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Abstract 
The cardiac sodium channel Nav1.5 plays a key role in cardiac excitability and 
conduction. Its importance for normal cardiac function has been highlighted by 
descriptions of numerous mutations of SCN5A (the gene encoding Nav1.5), causing 
cardiac arrhythmias which can lead to sudden cardiac death. 
The general aim of my PhD research project has been to investigate the 
regulation of Nav1.5 along two main axes: (1) We obtained experimental evidence 
revealing an interaction between Nav1.5 and a multiprotein complex comprising 
dystrophin. The first part of this study reports the characterization of this interaction. 
(2) The second part of the study is dedicated to the regulation of the cardiac sodium 
channel by the mineralocorticoid hormone named aldosterone. (1) Early in this study, 
we showed that Nav1.5 C-terminus was associated with dystrophin and that this 
interaction was mediated by syntrophin proteins. We used dystrophin-deficient mdx5cv 
mice to study the role of this interaction. We reported that dystrophin deficiency led to 
a reduction of both Nav1.5 protein level and the sodium current (INa). We also found 
that mdx5cv mice displayed atrial and ventricular conduction defects. Our results also 
indicated that proteasome inhibitor MG132 treatment of mdx5cv mice rescued Nav1.5 
protein level and INa in cardiac tissue. (2) We showed that aldosterone treatment of 
mice cardiomyocytes led to an increase of the sodium current with no modification of 
Nav1.5 transcript and protein level. 
Altogether, these results suggest that the sodium current can be increased by 
distribution of intracellular pools of protein to the plasma membrane (e.g. upon 
aldosterone stimulation) and that interaction with dystrophin multiprotein complex is 
required for the stabilization of the channel at the plasma membrane. Finally, we 
obtained preliminary results suggesting that the proteasome could regulate Nav1.5 in 
mdx5cv mice. This study defines regulatory mechanisms of Nav1.5 which could play 
an important role in cardiac arrhythmia and bring new insight in cardiac conduction 
alterations observed in patients with dystrophinopathies.  
Moreover, this work suggests that Brugada syndrome, and some of the cardiac 
alterations seen in Duchenne patients may be caused by overlapping molecular 
mechanisms leading to a reduction of the cardiac sodium current. 
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I.1 Motivation of the project 
The heart is a powerful specialized muscle which functions as a pump to 
transport oxygen and nutrients to all the parts of the body and removes waste 
products. The heart beats continuously throughout a lifetime, and adapts to variations 
in blood demands by increasing or decreasing the heart rate (HR) and contractility. 
On average, the heart beats more than 100,000 times each day pumping over 
10,000 liters of blood. However, many forms of heart disease can interrupt the normal 
cardiac cycle and cause abnormal electrical impulses. This irregular heart rhythm 
(arrhythmia) can cause the heart to suddenly stop beating and can lead to sudden 
cardiac death (SCD). The main goal pursued by the scientists in the laboratory is to 
decipher the molecular mechanisms underlying cardiac arrhythmias. Among the 
various ion channels implicated in cardiac arrhythmias, our attention is focused on 
the voltage-gated sodium channel Nav1.5 for its crucial role in cardiac cells 
excitability and conduction of the cardiac impulse. Its importance for normal cardiac 
function has been highlighted by the description of numerous mutations in SCN5A 
(the gene encoding Nav1.5), linked to various cardiac diseases such as the Brugada 
syndrome and the congenital long QT syndrome. Recently, several studies have 
shown that Nav1.5 is associated with other proteins forming multiprotein complexes 
that could be involved in regulation of channel activity, in correct cellular localization, 
or in protein degradation1-3.  
Understanding the physiological mechanisms of Nav1.5 regulation by interacting 
proteins is essential since it could improve diagnostic tools and constitute new 
pharmacological targets. In that context, the general aim of my PhD research project 
has been to identify and characterize partner proteins regulating Nav1.5. We have 
obtained experimental evidence indicating an interaction between Nav1.5 and a 
multiprotein complex comprising dystrophin. The first part of this thesis report is 
dedicated to the characterization of this interaction. 
In addition, during my PhD, I also investigated the regulation of the cardiac 
sodium channel by a hormone named aldosterone, and the results of these 
experiments are reported in the last part of this thesis. 
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I.2 Organization of the thesis 
This thesis report starts with a background section which introduces the 
essential concepts of cardiac physiology. This section also includes the description of 
the voltage-gated sodium channel Nav1.5 and the dystrophin multiprotein complex. 
The last part of the background section introduces an overview of the corticosteroid 
hormones and their potential role in cardiac physiology and diseases. This general 
introduction is followed by a detailed enumeration of the specific aims of the project. 
The results obtained during my PhD research project are presented as three 
original scientific publications. The first publication presents the characterization of 
Nav1.5 in dystrophin-deficient mice (Gavillet et al. 2006)4. The second publication 
reports the consequences of proteasome inhibitor treatment on dystrophin-deficient 
mice (Gavillet et al. in preparation). The third publication addresses the effects of 
aldosterone on the sodium current in mouse cardiomyocytes (Boixel, Gavillet et al. 
2006)5. The materials and methods used for the experiments are included in the ad 
hoc sections of each article. 
Discussion of publication results and future directions are presented in the last 
part of the thesis followed by a general conclusion on Nav1.5 regulatory mechanisms 
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II.1 The heart 
Over hundreds million of years, the heart has evolved from a simple contractile 
blood vessel as found in worms, to a highly specialized muscle composed of four 
chambers as found in mammals. The heart is constituted of four chambers: the right 
atrium and ventricle and the left atrium and ventricle (Figure 1A). The heart works as 
a double pump on the blood circulation since the left and right chambers are totally 
separated by the septa. The main function of the right side of the heart is to collect 
deoxygenated blood from the vena cavae in the right atrium, and pump it, via the 
right ventricle, into the lungs so that carbon dioxide can be released and the blood 
can be reoxygenated (Figure 1B). The left side collects oxygenated blood from the 
pulmonary veins in the left atrium and the left ventricle pumps it out to the body. The 
left ventricle is more powerful than the right as it has to pump the blood through the 
entire body, whereas the right ventricle only needs to pump blood to the lungs. Atria 
and ventricles are separated by valves (mitral on the left side and tricuspid on the 
right side) which prevent backflow of blood to atrium during ventricle contraction. 
Connected to the base of the aorta are found the coronary arteries which supply 
blood to the heart muscle itself. Indeed, even if blood does fill the chambers of the 
heart, the cardiac muscle tissue is so thick that it requires coronary blood vessels to 
deliver blood deep into the myocardium.  
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Figure 1: Representation of the heart and of the blood circulation. (A) The human heart is made 
of 4 chambers (right atrium, right ventricle, left atrium and left ventricle) and 4 valves. The left 
ventricle muscle is thicker than the right one (image from McGraw-Hill Companies). (B) The right side 
of the heart collects the de-oxygenated blood from the body and transports it to the lungs (pulmonary 
circulation). The left side collects the oxygenated blood from the lungs and transports it to the rest of 
the body (systemic circulation). 
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II.1.1 Cardiac cells 
The myocardium is composed of different cell types (Figure 2). Cardiomyocytes 
are the largest tissue fraction and account for 75% of the total volume of the 
myocardium but they only represent 30% of the total number of cardiac cells6. Other 
cardiac cell types consist of (1) fibroblasts (90% of non-myocytes cells) which 
produce the connective tissue and may participate in conduction7,  (2) endothelial 
cells which form the walls of the coronary vessels, the lymphatic vessels and the 
endocardium, (3) smooth muscle cells which are found in the epicardium and in the 
walls of the intramyocardial vessels,  (4) neurons and (5) inflammatory cells, mainly 
constituted by macrophages8, 9.  
 
Figure 2: Repartition of different cardiac cell types. Fibroblasts are the most abundant cells in the 
heart (63% of the total cell number). Cardiomyocytes represent 30% of the total cell number but they 
account for 75% of the myocardium volume. 
 
Several types of cardiomyocytes are found in the heart. Working myocytes are 
the most abundant (Figure 3) and are specialized for contraction. They are filled at 
85% with contractile elements named sarcomeres and mitochondria which provide 
the cell with energy10. The second type of cardiomyocyte is found in the His-Purkinje 
fiber system (Figure 6) and is specialized in the fast conduction of electrical signal. 
These cells have few contractile elements. The third cardiomyocyte type is 
constituted by nodal cells which are localized within the sinoatrial node (SA) and 
atrioventricular node (AV) and have a pacemaker activity11. 
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Noteworthy, a single cardiomyocyte isolated in a culture dish will spontaneously 
start to contract rhythmically. If two cells are in contact, the one that first contracts will 
stimulate the other and so on. This phenomenon is due to the electrical properties of 
cardiomyocytes that will be described in the following chapter. 
 
Figure 3: Drawing of a myocyte fiber. Cardiomyocytes are mainly constituted of sarcomeres and 
mitochondria. Cardiomyocytes are connected with each others by specialized structures called 
intercalated discs (image from physioweb.med.uvm.edu). 
II.1.2 The cardiac action potential 
In most animal cells, the plasma membrane (sarcolemma) maintains large 
gradients of ions between intracellular and extracellular environments. At rest, the 
inside of a cardiomyocyte is negatively charged and the outside is positively charged 
so that the cell membrane is polarized (~ -85 to -95 mV at rest) (Figure 4).  
The sarcolemma of cardiac cells comprises macromolecular proteins called ion 
channels which form pores that allow specific ions to flow in or out of the cell in a very 
efficient and selective fashion (up to 108 ions per second). Some of these ion 
channels are voltage-gated which means that they are activated by changes in the 
membrane potential. Once a cell is electrically stimulated by a current from an 
adjacent cell, voltage-gated channels are activated and the resting polarity of the cell 
is reversed. The rapid depolarization of the cardiomyocyte followed by repolarization 
is named the action potential (AP).  
10 
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Figure 4: Ionic balance in cardiomyocyte. The potassium concentration is much higher inside than 
outside the cell, whereas the sodium concentration is much higher outside than inside the cell. These 
ion concentrations are maintained by the activity of the sodium-potassium ATPase. 
 
The AP can be divided in 5 phases (numbered 0-4) where phase 4 is the resting 
membrane potential (Figure 5). The initial phase of depolarization allows the opening 
of the voltage-gated sodium channels which permits a flow of positive sodium ions 
within the cell (INa). This inward sodium current produces the rapid depolarization 
phase of the AP (phase 0, Figure 5). Thereafter, the cell is briefly repolarized by the 
opening of a particular class of potassium channels which generates a transient 
outward flow of positive potassium ions (Ito) (phase 1, Figure 5). The "plateau" phase 
(phase 2, Figure 5) of the cardiac AP is sustained by a balance between the inward 
movement of calcium (ICa) generated by the L-type calcium channels, and the 
outward movement of potassium (IKr and IKs) mediated by the slow delayed rectifier 
potassium channels12. The sodium-calcium exchanger (INa, Ca) and the sodium-
potassium pump (INa, K) are also involved during phase 2.  During phase 3 of the AP, 
the L-type calcium channels close, while the slow delayed rectifier potassium 
channels (IKs) are still open. This creates a net outward current which allows more 
types of potassium channels to open. These are primarily the rapid delayed rectifier 
potassium channels (IKr) and the inwardly rectifying potassium current (IK1). This 
outward current causes the cell to repolarize. The delayed rectifier potassium 
channels close when the membrane potential is restored to -80 to -85 mV, while the 
inward potassium channel (IK1) remains active during phase 4 to set the resting 
membrane potential. 
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Figure 5: Human cardiac action potential and ion channels. The cardiac action potential is 
divided in 5 phases (numbered 0-4). The genes encoding the ion channels are represented with the 
depolarizing (blue) and repolarizing (red) ionic currents. 
 
During the phase 0 and 1, the depolarization activates calcium channels, 
leading to inward calcium currents (i.e. ICa-L). The resulting changes in intracellular 
calcium activate the contraction machinery of cardiomyocytes in a process called the 
excitation-contraction coupling. The synchronized contraction of myocytes of different 
cardiac cavities is achieved by the cardiac conduction system. 
II.1.3 The cardiac conduction system 
In contrast to skeletal muscle, which requires a nervous stimulus, the heart has 
a myogenic activity, which means that it is self-excitatory. However, the frequency of 
the heartbeat can be affected by nervous or hormonal signals, for instance during 
exercise. Each time the heart beats, atrial and ventricular contraction are triggered by 
the propagation of an electric signal which depolarizes the cells one after the other 
12 
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 This wave of depolarization is initiated in the sinoatrial (SA) node, also known 
as the cardiac pacemaker, which is located in the upper wall of the right atrium 
(Figure 6). The electrical signal generated by the SA node is rapidly conducted 
through the atria to the atrioventricular (AV) node situated in the lower right atrium. 
Once the depolarization wave reaches the AV node, it is delayed before spreading 
along a specialized bundle of conducting fibers named the His bundle. The electrical 
impulse spread throughout the left and right bundles and triggers ventricular 
contraction. The delay at the AV node is necessary to allow all the blood in the atria 
to fill the ventricles. This sequence of electrical events (cardiac cycle) is repeated 
with every heartbeat13. 
Figure 6: Diagram of the cardiac conduction system. The electrical impulse generated by the 
sinoatrial (SA) node reaches the atrioventricular (AV) node where it is delayed before spreading in the 
bundle branches (modified from medicalcenter.osu.edu). 
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II.1.4 The electrocardiogram (ECG) 
The wave of conduction spreading from the SA node through the atria, to the 
AV node, and ultimately to the ventricles can be monitored by measuring voltage 
changes on the body surface, generating the so-called electrocardiogram (ECG). 
Today, the ECG is the standard clinical tool used to detect cardiac electrical 
abnormalities.  
A typical ECG of a normal heart cycle consists of the P wave, the PR interval, 
the QRS complex, the ST segment and the T wave (Figure 7).  The P wave is the 
electrical signature of the depolarization that causes atrial contraction. Both the left 
and right atria contract almost simultaneously. The period of inactivity between the P 
wave and the start of the QRS complex is termed the PR interval and reflects the 
slower rate of conduction through the AV node. The QRS complex reflects the 
depolarization of the ventricular muscle. Finally, the T wave reflects the repolarization 
of the ventricles14. The QT interval duration reflects the time taken by the ventricular 
mass (left and right) to depolarize and repolarize. Patients with prolonged QT 
intervals have prolonged ventricular action potentials and are susceptible to a form of 
tachycardia called “torsades de pointe”. This disorder, called the long QT syndrome, 
is caused by mutations of cardiac ion channel genes. In the next chapter is described 
the mutation of the gene encoding the voltage-gated sodium channel Nav1.5 which 
causes the congenital long QT syndrome type 3 (LQT3). 
 
Figure 7: Schematic representation of a normal electrocardiogram (image from A. Atkielski). 
14 
Regulation of the expression of Nav1.5, the cardiac voltage-gated sodium channel 
II.2 The cardiac voltage-gated sodium channel 
Nav1.5 
We have seen in the previous chapters that the cardiomyocyte contraction was 
the result of a delicate dynamic balance between opening and closing of many ion 
channels. Therefore, even a modest variation of the properties of one family of ion 
channel can have deleterious effects on the heart function. The cardiac pathologies 
associated with alteration of ion channels are called channelopathies.  
This section focuses on the cardiac voltage-gated sodium channel Nav1.5, 
which is the predominant sodium channel found in the heart. This channel plays a 
crucial role in initiation and duration of the action potential (AP). Nav1.5 is also 
essential for the conduction of electrical impulses. 
 
Voltage-gated sodium channels transport sodium ions into the cell and are 
activated by changes in the transmembrane electrical potential. They consist of one 
α-subunit and up to four smaller β-subunits called β1, β2, β3 and β4 (see chapter 
II.2.3.1) (Figure 13). The human genome contains 10 genes encoding α-subunits (i.e. 
Nav1.1 to Nav1.9 and Nax), which are mostly expressed in excitable cells15. The α-
subunit has four domains repeat, labeled I through IV, each containing six 
membrane-spanning regions, labeled S1 through S6 (Figure 8). The extracellular 
loop between S5 and S6 of each domain determines the channel's ionic selectivity16, 
17.  
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Figure 8: Structure of the voltage-gated sodium channel. (A)The α-subunit is composed of four 
homologous domains DI to DIV containing the transmembrane segments 1 to 6. The voltage sensor 
(S4) has several positively charged amino acid residues. The pore-forming region controls ion 
selectivity and transport. (B) Representation of the channel integrated in the membrane. 
 
Schematically voltage-gated sodium channels can be found in three 
conformational states: closed, open and inactivated (Figure 9A). Upon changes in 
transmembrane voltage, the S4 region undergoes a conformational change which 
opens the channel for a millisecond. During this time, ~7000 sodium ions pass 
through each channel (generating a current of 0.1 pA). Immediately after, the channel 
goes into the inactivated state until the cell repolarizes. The ability to inactivate is 
thought to be due to a plug (formed by domains III and IV of the alpha subunit), 
called an inactivation gate, that blocks the inside of the channel shortly after it has 
been opened (Figure 9B)18.  
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Figure 9: Gating states of the sodium channel. (A) The open, inactivated and close state of the 
channel. (B) Possible mechanism of inactivation of the channel by the inactivation gate (image from 
clabs.de and chemsoc.org)19. 
II.2.1 Pathophysiology of Nav1.5 
Today, more than one hundred mutations in SCN5A, the gene coding for Nav1.5, 
have been associated with distinct cardiac diseases20. Mutations of the voltage-gated 
sodium channel have been associated with the following channelopathies: (1) the 
congenital long QT type 3 (LQT3) and the Brugada syndromes21. Patients with a long 
QT syndrome have a history of syncopal episodes and show a prolonged QT interval 
on the ECG22. The Brugada syndrome is also described by syncopal episodes and/or 
sudden death in patients associated with a characteristic ECG displaying an elevated 
ST segment in the precordial leads V1 to V319. Noteworthy, only 10 to 30% of the 
Brugada patients display mutations in SCN5A23. (2) SCN5A mutations are also 
associated with cardiac conduction disorders such as impaired atrioventricular 
conduction (i.e. heart block)24, progressive cardiac conduction defect (i.e. altered 
cardiac conduction through His-Purkinje system)25 or sick sinus syndrome (i.e. sinus 
node dysfunction)26. Recently mutations of SCN5A have also been associated with 
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dilated cardiomyopathy (i.e. right ventricle or biventricular enlargement leading to 
ventricular dysfunction) although these results are still controversial27, 28. (3) Recent 
investigations have shown that SCN5A mutations were also implicated in certain 
cases of sudden infant death syndrome (SIDS)29.  
II.2.2 Role of the sodium current in the impulse conduction 
Nav1.5 also plays a crucial role in the conduction of the electrical impulse. 
Conduction measurements studies have shown at the macroscopic scale that 
slowing of conduction, a key ingredient of reentrant arrhythmias, may be caused by 
reduction of excitability and/or a reduction of gap junctional coupling30. In most of the 
myocardium, Nav1.5 sodium current is the major depolarizing current, therefore a 
decrease in the sodium current leads to a slowing of the conduction velocity which 
may promotes arrhythmias31. Using mathematical simulations of conduction Kucera 
and coll.32 have shown that the sodium current generated by Nav1.5 localized at 
intercalated discs of cardiomyocytes could modulate cardiac conduction. 
II.2.3 Regulation of Nav1.5 
Given the implication of the voltage-gated sodium channel in cardiac diseases, 
the proper regulation of the sodium channel by interacting proteins appears to be 
crucial for the cardiac function. Recent studies have reported proteins interacting with 
Nav1.5 which could be involved in the regulation of channel activity, the correct 
cellular localization, or in the process of degradation of the protein. This chapter 
describes proteins that have been reported to contribute to the regulation of Nav1.5.  
II.2.3.1 Beta-subunits 
The voltage-gated sodium channel is a heteromeric protein complex composed 
of α and β-subunits. However, the α-subunit alone can generate a sodium current in 
vitro and the composition of heteromeric complexes in vivo is still elusive. For these 
reasons, the β-subunits are described in this chapter as regulatory proteins. 
Four β-subunits have been identified in mammals33, 34, 35. The primary structure 
of β-subunits consists of a short cytoplasmic C-terminus, a single transmembrane 
segment and a large extracellular N-terminus domain. β-subunits have been 
implicated in the localization of Nav1.5 in heterologous systems and in the 
18 
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modification of the gating properties36. However the precise function of each subunit 
in a physiological context remains mostly unknown. 
II.2.3.2 Protein Kinases and Phosphatases 
The cAMP-dependent protein kinase A (PKA). Catecholamines regulate cardiac 
function by interacting with β-adrenergic G-protein coupled receptors (GPCR) which 
activate the cAMP-dependent protein kinase A (PKA) by downstream events. For this 
reason, the consequences of PKA activation on ion channels has been investigated 
by several group37. Murphy and coll.38 have shown in mammalian cells that the rat 
sodium channel could be phosphorylated by PKA on serines S526 and S529 (S525 
and S529 in human). Using Xenopus oocytes, two studies have shown that PKA was 
increasing the sodium current generated by Nav1.539,40. Yarbrough and coll.41 have 
used biochemical and microscopy techniques to reveal that the increased sodium 
current, resulting from Nav1.5 activation by PKA, was due to an increasing number of 
sodium channels at the plasma membrane. Finally, it was shown that activation of the 
sodium channel upon β-adrenergic stimulation could be mediated by a PKA-
independent pathway through the direct interaction of Gsα with the cardiac sodium 
channel42. The PKA ability to phosphorylate Nav1.5 seems established but further 
studied are needed to understand the physiological relevance of this phenomenon.  
 
The protein kinase C (PKC). PKC is a protein kinase that is activated by 
diacylglycerol synthesized after α1-adrenergic stimulation. Weigt and coll.43 have 
shown that α1-adrenergic stimulation of PKC was able to reduce the sodium current 
in guinea pig cardiomyocytes. Finally, another group has shown in mammalian cells 
that PKC phosphorylation of the rat sodium channel at residue S1505 (S1503 in 
human) was modulating the conductance and the gating properties44.  
 
Other protein kinases. The protein tyrosine kinase Fyn, which belongs to the Src-
family of tyrosine kinases, has recently been shown to modify the properties of 
Nav1.5. Using HEK293 cells, Ahern and coll.45 have shown that the FynCA (a 
constitutively active variant) induced a depolarizing shift of the steady-state 
inactivation curve of Nav1.5 which was abolished by mutation of tyrosine Y1495. The 
authors also reported that FynCA increased the tyrosine phosphorylation of Nav1.5.  
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The serum glucocorticoid inducible kinases isoforms 1 and 3 (SGK1 and SGK3), 
were shown to increase the sodium current in  Xenopus oocytes46. However direct 
evidence of Nav1.5 phosphorylation by SGK proteins remain to be demonstrated. 
 
The phosphatase PTPH1. Our group has recently shown that the protein tyrosine 
phosphatase PTPH1, which is expressed in the heart, could interact with the PDZ-
domain binding motif of Nav1.5. We showed that co-expression of PTPH1 and Nav1.5 
in HEK293 cells could modulate the stability of the inactivated state of the channel47. 
Altogether these results indicate that the function of Nav1.5 can be regulated by the 
level of tyrosine phosphorylation. 
II.2.3.3 Ubiquitylation 
Ubiquitin ligases 
Ubiquitin is a small (7 kDa) highly conserved protein that is ubiquitous in 
eukaryotes. Recently, our group has shown in HEK293 cells that the E3 ubiquitin–
protein ligase Nedd4-2 could directly bind the PY-motif of Nav1.5 and ubiquitylate the 
channel3. In addition, we have shown that Nedd4-2 could increase the internalization 
rate of Nav1.5 channels expressed in mammalian cells47. Finally, we found that a 
fraction of Nav1.5 was ubiquitylated in cardiac tissue, suggesting that regulation of 
Nav1.5 density at the plasma membrane could be controlled in vivo by its 
ubiquitylation3. The ubiquitin ligases are referred to as E3 and operate in conjunction 
with E1 ubiquitin-activating enzymes and E2 ubiquitin-conjugating enzymes (Figure 
10). The E1 enzymes use ATP to activate ubiquitin for conjugation and transfer it to 
E2 enzymes. E2 enzymes interact with specific E3 partners which transfer ubiquitin 
to the target protein48.   
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Figure 10: Diagram illustrating the hypothetic model of regulation of Nav1.5 by ubiquitylation. 
Ubiquitin is carried by E1, E2, and E3 enzymes. For the family of Nedd4/Nedd4-like E3 enzymes the 
specific interaction takes place between one of the WW domains and the PY motif of Nav1.5. The C2 
domain is thought to provide calcium-dependent binding to membrane phospholipids. This model 
proposes that Nedd4/Nedd4-like enzymes ubiquitylate Nav1.5, and that ubiquitylated proteins are 
recognized by the internalization machinery.  
Ubiquitin sorting signals 
Ubiquitylation was first shown to tag cytosolic proteins for rapid degradation by 
the proteasome. But ubiquitylation is also involved in a variety of other cellular 
processes such as, for example, protein biosynthesis, and trafficking. Most of the 
time, ubiquitin is covalently attached to lysines of targeted proteins. Proteins may be 
conjugated to monoubiquitin moieties alone or to polyubiquitin chains. However, the 
consequences of monoubiquitylation versus polyubiquitylation of proteins is still 
controversial, for example, it is not clear whether the number of ubiquitin units 
(polyubiquitin) could increase signal efficiency and further stimulate rapid 
internalization of membrane proteins. Finally, ubiquitylation is a reversible process 
facilitated by deubiquitylating enzymes (DUB)49. Ubiquitylation is involved in the 
following cellular processes: 
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(1) Internalization and degradation of membrane associated proteins. 
Monoubiquitylation of a plasma membrane protein is sufficient for its internalization. If 
not removed by deubiquitylating enzymes, monoubiquitylation of internalized plasma 
membrane protein is sufficient for targeting the protein to lysosomal proteolysis 
(Figure 11). The lysosomal apparatus is a membrane enclosed vacuole which 
contains multiple proteases and which is thought to be the primary site for 
degradation of membrane associated proteins or extracellular proteins taken by 
endocytosis 50. 
Figure 11: Diagram illustrating the regulation of membrane associated proteins by ubiquitin. 
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(2) Degradation of cytoplasmic proteins. It is thought that polyubiquitylation is a 
signal for the recognition and the degradation of cytoplasmic proteins by the 
proteasome. The proteasome apparatus is a protein complex present in both the 
cytoplasm and the nucleus which has several protease activities51. 
(3) Regulation of the endocytic machinery. The conclusion that ubiquitylation 
regulates the activity of the endocytic machinery comes from observations that 
ubiquitylating enzymes are required for the endocytosis of proteins that do not 
require attachment of a ubiquitin-sorting signal (e.g. The growth hormone receptor52). 
Several endocytic proteins were shown to be modified by ubiquitylation such as β-
arrrestin, Eps15 and Epsin53-55. In addition, the proteasome is also probably 
implicated in the regulation of these endocytic proteins56. However, components of 
the endocytic machinery that undergo ubiquitylation are primarily monoubiquitylated 
and proteasome recognises polyubiquitylated proteins. It was therefore suggested 
that endocytic proteins could be transiently polyubiquitylated and degraded by the 
proteasome 57. 
(4) Sorting of intracellular resident proteins from the trans-Golgi network (TGN) 
to endosomes or lysosomes. Even if the role of ubiquitin in sorting proteins from the 
TGN to endosomes or lysosomes in not clear in mammalian, studies in yeast indicate 
that ubiquitylation serves as an important signal for targeting proteins to vacuole 58, 59. 
(5) Endoplasmic reticulum associated degradation of misfolded proteins (ERAD). 
Misfolded membrane proteins are recognized by a quality control system in the 
endoplasmic reticulum (ER) and are polyubiquitylated before being degraded by the 
proteasome (reviewed in Abriel and coll.60). The CFTR chloride channel was the first 
membrane protein studied for the understanding of the molecular mechanisms of 
ERAD61, 62. CFTR is a large protein with many transmembrane domains which is 
inefficiently biosynthesized and an important fraction of the protein is misfolded and 
degraded in the ER. Cytosolic chaperones (Hsc70 and Hsp40) recognize the 
misfolded region of the channel and recruit the ubiquitin protein ligase CHIP. This 
promotes ubiquitylation of the channel and leads to retrotranslocation and 
degradation by the proteasome (Figure 12).  
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Figure 12 : Molecular mechanisms involved in CFTR ER-associated degradation. Misfolded 
CFTR, comprising the cytosolic nucleotide-binding domains 1 and 2 (NBD 1 and 2) and the regulatory 
R domain, is recognized by the cytosolic chaperone Hsc70 and the cochaperone Hsp40, which 
recruits the ubiquitin-protein ligase CHIP, containing a U-Box, and the E2 enzyme UbcH5a. Other E3 
ligases, such as Doa10 (in concert with Ubc6) and Der3/Hrp1 and SCF(Fbx2) likely play a role in 
recognition and ubiquitylation of CFTR. Upon ubiquitylation CFTR is retrotranslocated through the 
transmembrane protein channel Sec61 with the assistance of the cytosolic p97/Ufd1/Npl4 complex. 
P97/Ufd1/Np14, the Hsc70 associated protein BAG-1, and likely the polyubiquitin chains of CFTR 
promote the transfer to the proteasome and CFTR degradation (from Abriel et al.60). 
 
II.2.3.4 The protein 14-3-3 
14-3-3 proteins are highly conserved ubiquitous proteins that can interact with 
numerous cellular proteins and are crucial for cell signaling and ion-channel 
regulation63. Using two-hybrid screen and co-immunoprecipitation experiments, a 
recent study has shown that 14-3-3 proteins were interacting with a region of the 
cytoplasmic loop linking domains I and II of Nav1.5 (Figure 13)64. The authors 
showed that Nav1.5 and 14-3-3 proteins were colocalized in rabbit cardiomyocytes 
and that co-expression of both proteins induced a negative shift in the inactivation 
curve of the sodium current and a delayed recovery from inactivation. 
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II.2.3.5 Ankyrin 
Ankyrins are ubiquitously-expressed proteins which associate with diverse 
membrane, cytoskeletal, and cytoplasmic proteins. Two ankyrin isoforms are found in 
cardiomyocytes: the predominant 220-kDa ankyrin-B, and the 190-kDa ankyrin-G1. 
Recently, It has been shown that Nav1.5 could interact with ankyrin-G in expression 
systems (Figure 13)65. Mohler and coll.66 have reported that mutation E1053K, which 
is associated with a Brugada syndrome, inhibits the binding of ankyrin-G to Nav1.5 
and prevents the normal localization of the channel at intercalated discs of rat 
cardiomyocytes. Altogether these results suggest that ankyrin-G could play a major 
role in the trafficking and the stabilization of Nav1.5 at the membrane of 
cardiomyocytes. 
II.2.3.6 Fibroblast growth factor homologous 1B 
The fibroblast growth factor homologous 1B (FHF1B) has been shown to bind to 
the C-terminus of the cardiac voltage-gated sodium channel Nav1.5 (Figure 13) and 
to modulate the properties of the channel. This is the first and only report of a growth 
factor modulating the sodium channel67. 
II.2.3.7 Calmodulin 
The sodium channel Nav1.5 bears an IQ-motif that binds calmodulin (Figure 13). 
Although this interaction is well described, the modulation of the biophysical 
properties of Nav1.5 by calmodulin is still controversial and further studies need to be 
performed in order to elucidate the physiological role of calmodulin in the regulation 
of Nav1.568, 69.  
II.2.3.8 Syntrophin proteins 
Syntrophins are cytoplasmic adaptor proteins expressed in skeletal and cardiac 
cells. Currently, five isoforms of syntrophins: α1, β1, β2, γ1 and γ2 have been 
identified but only α1, β1 and β2 syntrophins were detected in mouse 
cardiomyocytes70. Syntrophins bear a unique C-terminus sequence that allow binding 
to dystrophin, utrophin and dystrobrevin as well as a PDZ domain allowing an 
interaction with ion channels and other signaling molecules71, 72.  
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The interaction of Nav1.5 with syntrophins in the heart was first documented by 
Gee and coll.73. The authors performed biochemical experiments on muscular and 
cardiac proteins extract and they purified a complex formed by the sodium channel, 
syntrophin, and dystrophin73. The functional role of this interaction has been 
assessed in two studies. In the first study, Zhou and coll.74 used Xenopus oocytes to 
measure the currents generated by truncated sodium channels for which the PDZ 
binding domain was truncated. The authors reported that the steady state inactivation 
was shifted by -5mV and that the time course of inactivation was slowed in the 
truncated Nav1.5 (thus in absence of binding to syntrophins). In the second study75, 
the authors indicated that the expression of γ2-syntrophin and Nav1.5 in mammalian 
cells shifted the steady-state activation toward positive potentials, but had no other 
effect on the other biophysical parameters of the sodium channel.  
The different isoforms of syntrophin proteins bind to a variety of molecules 
however the isoform composition varies between tissues and the isoforms are 
expressed in different cell compartment (e.g. in skeletal muscle, α1-syntrophin is 
expressed on the sarcolemma of all fibers whereas β1-syntrophin is expressed at the 
sarcolemma of only type II fibers and β2-syntrophin is expressed at the level 
neuromuscular junction76, 77). Thus far, no study has reported the cellular localization 
of the different syntrophin isoforms in cardiac cells. As previously mentioned, 
syntrophin proteins are members of the dystrophin-multiprotein complexes (DMC) 
which will be described in the next chapter. 
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Figure 13: Diagram of proteins interacting with Nav1.5. β1 and β2 subunits are represented (the 
extracellular domain of the β1 subunit interacts with the α-subunit loop and the β2 subunit binds 
covalently to the α-subunit via a disulfide bound). The sites of interaction of 14-3-3, ankyrin, FHF1B, 
calmodulin, syntrophins and ubiquitin ligases of the Nedd-4 family are indicated by red circles. 
Phosphorylation sites of PKA, SGK, FYN and PKC are also represented. 
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II.3 The dystrophin protein 
As mentioned above, Nav1.5 is interacting with syntrophin proteins. The main 
role of syntrophins is to bring in close proximity different types of proteins (such as 
ion channels) and dystrophin at the plasma membrane. Dystrophin is associated with 
various proteins which are described in this chapter. 
II.3.1 Gene sequence 
Dystrophin is a very large protein of 427 kDa encoded by the largest gene (the 
DMD gene) described in humans. It spans ~2.5 million base pairs of genomic 
sequence which corresponds to ~0.1% of the genome and ~1.5% of the X 
chromosome, where it is located (Figure 14A)78. The DMD gene comprises 86 exons 
and 99% of the gene is made of introns79. Three promoters drive the transcription of 
the 14 Kb full length mRNA in muscle, brain and cerebellar Purkinje cells. In addition, 
internal promoters generate shorter dystrophin transcripts and alternative splicing 
generates an even greater number of isoforms (Figure 14B)80, 81. The full length 
dystrophin protein is predominantly expressed in skeletal and cardiac muscle with 
small amounts expressed in the brain82, 83.  
28 
Regulation of the expression of Nav1.5, the cardiac voltage-gated sodium channel 
Figure 14: Genomic organization of the dystrophin gene. (A) Black vertical lines represent the 79 
exons of the dystrophin gene distributed over ~2.5 million base pairs. The arrows indicate the various 
promoters: brain (B), muscle (M), and Purkinje (P) promoters; R, B3, S, and G represent the Dp260 
(retinal), Dp140 (brain3), Dp116 (Schwann cells), and Dp71 (general) promoters. (B) The domain 
composition of the various dystrophin proteins is indicated. The amino-terminal domain is followed by 
the spectrin like domain, the cystein rich, and the C-terminal domain (from Muntoni and coll.84). 
II.3.2 Structure 
The dystrophin protein can be divided in three distinct regions (Figure 15). (1) 
The actin-binding region, localized at the N-terminus can bind F-actin85; (2) the long 
central rod-shaped region is composed of 24 repeats of triple helical domains similar 
to spectrin. This region constitutes the major part of the dystrophin protein and is 
interrupted by four proline-rich region that constitute potential hinges86. (3) The C-
terminus region is composed of a WW domain which is a protein-protein interaction 
domain known to interact with particular protein motifs such as the PY-motifs87, 88.  
The WW domain mediates the interaction with β-dystroglycan (a protein of the 
dystrophin multiprotein complex) which bears a PY-motif; however, the integrality of 
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the domain is not required to bind β-dystroglycan but the WW domains do require the 
adjacent EF-hand region of dystrophin for ligand binding89-91. Next to the WW domain 
is a cysteine rich region which contains two EF-hand motifs and a ZZ domain similar 
to zinc finger domains that has the ability to bind calmodulin92. Finally, the C-terminus 
has a coiled-coil region which bears the binding sites for dystrobrevin and several 
binding sites for syntrophins93.  
 
Figure 15: Diagram of the dystrophin protein. The dystrophin protein is composed of an actin 
binding region at the N-terminus and a central rod shaped region with four hinges (1-4). The C-
terminus of the protein contains a WW domain, a cystein rich region (CYS) bearing two EF hands and 
a ZZ domain, and a coiled-coil region (CC). The binding sites are shown for β-dystroglycan (DG) and 
syntrophin (SYN) (modified from Blake and coll. 200294). 
II.3.3 Dystrophin associated proteins 
Dystrophin and associated proteins constitute the dystrophin multiprotein 
complex (DMC) (Figure 16). The DMC, which is constituted by at least ten proteins, is 
thought to constitute a scaffold connecting the inside of a myocyte to the outside. The 
complex can be divided into three groups of proteins: the dystroglycan complex, the 
sarcoglycan-sarcospan complex and the cytoplasmic complex. 
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Figure 16: Diagram of the dystrophin multiprotein complex (DMC). αDG, α-dystroglycan; βDG, β-
dystroglycan; αβγδ-SG, sarcoglycan complex; SS, sarcospan; Syn, syntrophin. 
 
The dystroglycan complex. The dystroglycan complex is constituted of α-
dystroglycan (α-DG, 156kDa) and β-dystroglycan (β-DG, 43kDa) which are encoded 
by a single gene95. α-DG is a heavily glycosylated extracellular protein which binds to 
laminin, thus anchoring the DMC to the basal lamina (Figure 16)96. β-DG is a 
membrane protein with a cytoplasmic C-terminus which bears a proline rich region 
comprising a PY-motif necessary for the interaction with the dystrophin WW-domain 
and EF-hands97, 91. β-DG also binds to the adaptor protein Grb2 which also contains 
a WW-like domain, therefore it was suggested that β-DG and the DMC could play a 
role in signal transduction98. However, so far no experimental evidence supports this 
hypothesis. Interestingly, a study has shown that dystrophin inhibited the interaction 
between Grb2 and β-DG, suggesting that the two proteins could bind the same 
region of β-DG (the 20 last amino acids) or that Grb2 could regulate the interaction 
between β-DG with dystrophin99.  Recently, caveolin-3, which is a membrane protein 
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implicated in the formation of caveolae that also contain a divergent WW domain, 
was shown to compete with dystrophin for the binding to β-DG100. Mutations in 
caveolin-3 cause limb-girdle muscular dystrophy (LGMD2) which is often associated 
with a reduction in the levels of the DMC members, providing further evidence of the 
interaction between caveolin-3 and the DMC101.   
 
The sarcoglycan-sarcospan complex. In cardiac and skeletal muscle, the 
sarcoglycan complex is formed by four transmembrane proteins α, β, γ and δ-
sarcoglycan  associated with a member of the tetraspan family of proteins called 
sarcospan (Figure 16)102, 103. The structural organization and the function of the 
complex are still unclear. Mutations in each sarcoglycan gene have been associated 
with LGMD2104. Several studies using dystroglycan deficient animals indicate that the 
sarcoglycan-sarcospan complex is important for anchoring or stabilizing the 
dystroglycan complex in the sarcolemma105, 106. 
 
The cytoplasmic complex. In the cytoplasm, dystrophin interacts with syntrophins, 
dystrobrevin and actin (Figure 16). The interaction with actin confers the DMC its 
mechanical function, linking the extracellular basal lamina to the intracellular actin 
cytoskeleton. α-Dystrobrevin 1, 2 and 3 (α-DB1, α-DB2 and α-DB3) are 87 kDa 
proteins which share significant sequence homologies to the dystrophin C-
terminus107. Dystrobrevin proteins can interact with both dystrophin and syntrophins 
via their C-terminus108. α-DB3 is the cardiac isoform, but its localization is unclear 
since this isoform lacks the coiled-coil domain which is thought to mediate the 
interaction with dystrophin and syntrophin109. The precise role of the dystrobrevins in 
relation to the DPC at the sarcolemma remains mostly unknown since mice lacking 
α-dystrobrevin only develop mild muscular dystrophy without perturbing the assembly 
of other components of the DMC. 
In the cytoplasm, dystrophin is binding to the syntrophin proteins (see section 
II.2.2.8). Recently, it has been shown that there are two syntrophin-binding sites in 
the C-terminus of dystrophin (and an additional two sites on α-dystrobrevin)110. The 
syntrophins have been shown to bind to a variety of proteins such as nNOS, ion 
channels and calmodulin; most of these interactions occur through the PDZ domain 
of syntrophin and the C-terminal tail of the interacting proteins111. 
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II.3.4 Mutations in dystrophin 
II.3.4.1 Human dystrophinopathies 
The large size of the dystrophin gene significantly contributes to its high rate of 
spontaneous mutations. In humans, mutations in dystrophin are associated with the 
Duchenne (DMD) and the Becker muscular dystrophy (BMD), and the X-linked 
dilated cardiomyopathy (XLDCM).  
DMD is the most common lethal childhood disease affecting 1 of 3500 boys 
worldwide. Mutations that cause DMD generally result in the absence, or much 
reduced levels, of dystrophin. The first symptoms usually appears at the age of 2 to 5 
years; subsequently, DMD patients loose ambulation ability at the age of 10 years112.  
There is a cardiac involvement (CI) in ~90% of patient with DMD, due to 
progressive replacement of myocardial fibers by connective tissue and fat113. 
However, heart failure is a terminal event in only 10-20% of the cases114. 
BMD shows a milder phenotype than DMD mostly because patients generally 
synthesize some partially functional protein. More than 90% of patients are still alive 
in their twenties, with some patients remaining mobile until old age94. It appears that 
up to 90% of the BMD patients develop CI and heart failure is estimated to be a 
terminal event in ~50% of the cases115. 
The X-linked dilated cardio-myopathy (XLDCM) is characterized by a mutation 
in the muscle-specific promoter that selectively abolishes the cardiac expression of 
dystrophin, while retaining expression in skeletal muscle. Patients with XLDCM show 
ventricular wall dysfunction, dilated cardiomyopathy, and cardiac failure in the 
absence of skeletal myopathy116.  
II.3.4.2 The mdx and mdx5cv mouse strain 
The mdx mouse is a dystrophin-deficient model used for studying the human 
dystrophinopathies. The mdx mouse carries a premature stop codon in exon 23 of 
the dystrophin gene which occurred spontaneously in a C57BL/10ScSn mouse in 
1977 at the Agricultural Research Council's Poultry Research Centre, U.K. However, 
this strain was shown to have revertant fibers due to exon skipping events117. 
Therefore, other mice strains are being used, such as the mdx5cv mouse which is a 
C57BL/6Ros strain carrying an A to T mutation in the middle of exon 10 that 
produced a new splice donor site and generates a premature stop codon in full-
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length transcripts118. Although the lifespan of mdx mice is not grossly reduced, these 
mice show multiple muscle dysfunctions. Mdx mice show muscle hypertrophy, 
reduced muscular force production, muscle fiber necrosis with centrally nucleated 
fibers119, 120.  
Even if the mdx mice show many features of DMD, the phenotype differences 
between human and mice could be attributed to faster rates of muscle regeneration  
in mice121. Nevertheless, the mdx mouse remains a key resource to explore the 
dystrophic pathophysiology.  
II.3.4.3 DMD and mdx pathophysiology 
DMD and mdx muscles are characterized by fragile and leaky cell membranes 
that allow macromolecules to flow in and out of the cell, and this phenomenon is 
worsen by mechanical stress122, 123. DMD and mdx muscle also show oxidative 
damages124. 
Despite conflicting data, it is generally accepted that, due to membrane leak, 
the [Ca2+]i is raised in dystrophin-deficient muscle, leading to the activation of 
calcium-dependent proteases such as calpain125, 126.  Protein degradation has been 
shown to occur ~80% faster in mdx than in control mice, and the proteolysis was 
shown to be reduced by lowering the extracellular calcium concentration127. 
Moreover this effect was shown to be blocked by leupeptin (a protease inhibitor)128. 
However, all these studies were conducted in vitro, and direct evidence of calpain 
activity in dystrophin deficiency remains to be demonstrated. Despite the fact that the 
expression of components of the ubiquitin proteasome system was not found to be 
increased in dystrophin-deficient muscles, Bonuccelli and co-workers129 have shown 
that in vivo treatment of mdx mice with the proteasome inhibitor (MG132) was able to 
restore the expression and the proper localization of dystrophin and other 
components of the dystrophin glycoprotein-complex. Additionally, Assereto and 
coll.130 have recently demonstrated that MG132 treatment of DMD and BMD biopsies 
could restore the dystrophin protein complex. Altogether these results highlight the 
important role that could play protease inhibitors in the pharmacological treatment of 
DMD and BMD. 
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As a general mechanism for the DMD and mdx pathophysiology, it is proposed 
that the primary problem is the abnormal permeability of muscle cells (worsened by 
exercise) which alters calcium homeostasis leading to an increased protease activity. 
This in turn, triggers necrosis or apoptosis. 
II.3.4.4 Therapeutic strategies for Duchenne and Becker dystrophies 
Twenty years after the discovery of the etiology of DMD/BMD, no efficient 
therapy is able to restore dystrophin in humans. However, several approaches have 
been developed in attempt to compensate dystrophin deficiency (reviewed in131). 
First, “gene therapy” methods were developed to restore dystrophin expression 
in muscle fibers. These methods consist in introducing the dystrophin cDNA in the 
muscle, either by direct injection or using viral vectors. Limitation of these 
approaches have been the low number of fibers expressing dystrophin and the 
activation of the immune response following viral infection132. Other techniques 
involving RNA/DNA or antisense oligonucleotides have also been developed to 
correct point mutations or to induce exon skipping events133. Another therapeutic 
approach that has been developed is the “cell therapy”, which consists in delivering 
normal cells to the dystrophic muscle. Studies have investigated the effect of 
myoblasts (muscle cells precursors) injections in dystrophic muscles, however further 
characterization is still required before clinical trials can be envisioned134, 135. Several 
pharmacological compounds have been developed to compensate for the dystrophin 
deficiency such as protease inhibitors, drugs inducing the proliferation of satellite 
cells or drugs inducing the expression of the dystrophin homologue utrophin 136-138.   
Due to a need for further development none of these therapeutic approaches is 
currently being used to treat DMD patients. Today, glucocorticoids administration is 
the only treatment proposed to slow the progression of DMD. In particular, treatment 
of DMD patients with deflazacort® has been shown to improve the function of 
respiratory muscles139.  
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II.4 Aldosterone in the heart 
In the heart, hormones have also been shown to modulate ion channel 
functions. In particular, aldosterone, a mineralocorticoid hormone was shown to 
modify cardiac calcium and potassium currents140, 141. In addition aldosterone was 
shown to be increased in patients with heart failure (HF) and recent clinical studies 
have shown the beneficial treatment of HF patients with mineralocorticoids receptor 
(MR) antagonists142, 143. Therefore this chapter describes the characteristics of 
mineralocorticoid and glucocorticoid hormones. 
II.4.1 Corticosteroid hormones 
Glucocorticoids and mineralocorticoids constitute the two classes of 
corticosteroid hormones. Glucocorticoids are synthesized from cholesterol in the 
zona fasciculata of the adrenal cortex (Figure 17 and Figure 19). Glucocorticoid 
production is stimulated by the adrenocorticotropic hormone (ACTH). Cortisol is the 
main glucocorticoid synthesized in humans, whereas corticosterone is the most 
abundant in rodents. Glucocorticoid were first named for their ability to increase 
glucose plasma levels however they have numerous other effects on most body 
tissues such as immunosuppressive and anti-inflammatory activity, effect on protein 
metabolism, behavioral effect on the central nervous system (CNS), and effect on 
calcium and bone metabolism. In order to mimic the effects of the glucocorticoids, 
numerous synthetic drugs (such as prednisone and dexamethasone) have been 
developed to treat many different diseases.  
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Figure 17 :  Anatomy of the adrenal gland. An adrenal gland sits upon each kidney. The adrenal 
cortex comprises three layers that surround the medulla. The outermost layer contains the 
glomerulosa cells that secrete aldosterone, and the two inner layers of cortex (fasciculata and 
reticularis) synthesize cortisol and sex steroids (from Boron and coll. 2004144). 
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Aldosterone is a mineralocorticoid hormone (named for the ability to regulate 
body salt balance). The most well-known action of aldosterone is to stimulate sodium 
absorption and potassium secretion in the distal tubule and the collecting duct of the 
nephron. Sodium in the extracellular space retains water, thus the amount of sodium 
determines the volume of extracellular fluid, and since extracellular volume is a major 
determinant of arterial blood pressure, aldosterone plays a critical role in the 
maintenance of blood pressure.  
The glomerulosa cells of the adrenal cortex synthesize aldosterone from 
cholesterol in a series of five steps (Figure 18).  Glomerulosa cells are the only ones 
that contain aldosterone synthase, thus these cells are the exclusive site of 
aldosterone synthesis (Figure 17). The aldosterone synthase is a mitochondrial 
enzyme which converts corticosterone to aldosterone. There is no storage pool of 
aldosterone in the body, thus the secretion of aldosterone is limited by the rate at 
which glomerulosa cells can synthesize the hormone. There are three main factors 
that can influence aldosterone synthesis. The most important is the angiotensin II 
peptide which is a product of the renin-angiotensin system. An increase in the 
potassium plasma level can also induce aldosterone secretion. Finally, the hormone 
ACTH has a minor effect on aldosterone secretion. 
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Figure 18 : Biosynthesis of adrenal steroids. This schematic summarizes the synthesis of adrenal 
steroids (the mineralocorticoid aldosterone and the glucocorticoid cortisol) from cholesterol. The 
individual enzymes are shown in the horizontal and vertical boxes (from Boron and coll. 2004144). 
 
II.4.2 Corticosteroid receptors 
Aldosterone, like cortisol, acts mainly by modulating gene expression. These 
hormones, which are lipophylic enough to cross the plasma membrane without 
requiring a membrane transporter, bind to intracellular receptors. In the kidney, 
aldosterone binds to a type 1 receptor with a high affinity (Kd = 0.5 to 2 nM) and a 
type 2 receptor with a low affinity (Kd = 14 to 60 nM). The low affinity receptor 
appears to be identical to the glucocorticoid receptor (GR). The high affinity receptor 
is a distinct mineralocorticoid receptor (MR) which has homologies to the GR.  
In absence of hormone, the MR interacts with a protein complex comprising the 
90-kDA heat shock protein (HSP90) (Figure 19). Binding to aldosterone modify the 
conformation of the MR which lead to the release of the HSP90 protein. Then, the 
receptor acts as a transcription factor. MR and GR bind as dimers to specific DNA 
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sequences named hormone response elements (HRE) to induce activation of 
targeted genes (reviewed in Farman and coll. 1999145). Aldosterone has been 
proposed to act by two separate mechanisms: a genomic pathway (which consist of 
activating targeted genes) and a non-genomic pathway which was shown to activate 
secondary messengers (calcium, cAMP, IP3) in a very short time. However it is not 
clear whether this second pathway involves the MR receptors or another type of 
receptor which remains to be identified146. 
 
Figure 19: Action of steroid hormones. The activated steroid-hormone receptor binds to specific 
stretches of DNA called steroid-hormone response elements, which stimulates the transcription of 
appropriate genes. Hsp, heat shock protein, mRNA messenger RNA (modified from Boron and 
coll.144). 
 
In the kidney, cortisol (or corticosterone) binds with the same affinity as 
aldosterone to type 1 receptor and with a higher affinity to type 2 receptor. 
Conversely, aldosterone binds very weakly to the type 2 receptor (GR), thus having 
no significant glucocorticoid effect. Because the cortisol normally circulates at much 
higher concentration than aldosterone (140 to 560 nM versus 0.05 to 0.2nM), type 1 
receptors would be constantly occupied by cortisol without a protective mechanism. 
To avoid this effect, cells targeted by aldosterone (such as the epithelial cells of the 
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cortical collecting duct of the kidney) express the 11β-hydroxysteroid dehydrogenase 
type 2 (11β-HSD2). The 11β-HSD2 metabolizes cortisol (or corticosterone) into 
cortisone which has only 0.3% of activity to the MR (Figure 20) 147. 11β-HSD2 is very 
efficient at converting cortisol into cortisone and leads to a low cortisol/aldosterone 
ratio, locally in aldosterone targeted tissue as compared to the cortisol dominance 
observed in plasma. Therefore, the expression of 11β-HSD2 allows the 
mineralocorticoid action of aldosterone. Another enzyme, the 11β-HSD1 has the 
ability to convert cortisone into cortisol148. As a result, it is the balance between 11β-
HSD1 and 11β-HSD2 expression that regulates MR occupancy by aldosterone. 
 
 
Figure 20: The enzymatic actions of 11β-hydroxysteroid dehydrogenase on its substrates. 
Cortisone has only 0.3% of activity to the MR as compared to cortisol. 
II.4.3 Synthesis and action of aldosterone in the heart 
Beside corticoadrenal synthesis, recent studies have proposed that aldosterone 
is also produced in extra-adrenal tissues such as cardiac tissues, blood vessels and 
brain (reviewed in Firsov and coll. 2003149). Silvestre and coll.150 have been the first 
to report a cardiac production of aldosterone. The authors reported that: (1) 
aldosterone synthase was expressed in rat cardiac tissue but the mRNA levels were 
about 500 times lower than in the adrenal gland; (2) aldosterone concentration in the 
heart could be as high as 16 nM (whereas the plasma concentration is 0.1-1 nM); (3) 
cardiac aldosterone production was regulated by the same stimuli as adrenal glands 
(angiotensin II and potassium). Others studies also reported that aldosterone 
synthase mRNA was detected in failing adult hearts151. However in 2004, Gomez-
Sanchez and coll.152 reported that in healthy rat hearts, the level of aldosterone was 
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significantly lower than previously reported by Silvestre and coll. and that it reflected 
plasma concentration. The authors also reported that corticosterone was 
undetectable in adrenalectomized rats hearts (and plasma) and that aldosterone was 
detectable in about 30% of adrenalectomized hearts. This last finding would suggest 
that the heart is able to synthesize very small amounts of aldosterone; however the 
fact that corticosterone (which is 400 times more concentrated than aldosterone in 
intact heart) is undetectable in adrenalectomized hearts, suggests that no significant 
synthesis of corticosteroids occurs in the heart. 
Even if an autocrine action of aldosterone in the heart seems unlikely to occur, 
several studies suggest that circulating aldosterone could act on the heart. MR and 
GR expression has been shown in heart but the precise localization is still unclear. 
Lombes and coll. have reported that (1) in human the mRNA and protein of MR is 
expressed in cardiomyocytes but not in blood vessels153 ; (2) in rabbit the MR is 
localized in cardiomyocytes and in vessels (aorta and pulmonary artery)154. In 
addition Kohler and coll.155 have reported that MR mRNA could be detected in rat 
cardiomyocytes and cardiofibroblasts. However most of the cells expressing MR also 
express GR thus the specificity of aldosterone action also relies on the expression of 
the 11-βHSD2. Lombes and coll.153 have reported the presence of 11-βHSD2 
enzymatic activity in human heart (100-fold lower than in typically aldosterone-
sensitive renal collecting duct). In rat, 11-βHSD2 activity was documented in heart156, 
in cardiac fibroblasts157 and in vascular and cardiac smooth muscle158. However 
other studies have reported that 11-βHSD2 was absent in heart 159-161. Therefore it is 
difficult to be conclusive as to whether cardiac 11-βHSD2 is present in the heart and 
if it can protect MR from glucocorticoid occupancy.  
Even if the mechanisms of aldosterone action in the heart remain unclear, 
clinical evidence shows that the level of cardiac aldosterone can be found increased 
in patients with heart failure (HF)162, and that treatment of HF patients with MR 
antagonists (spironolactone143 and eplerenone142) reduces morbidity and mortality. It 
has been therefore hypothesized that hyperaldosteronemia may have direct or 
indirect proarrhythmogenic properties by promoting structural and/or functional 
remodeling in cardiac tissue. In particular, several studies have reported that 
aldosterone could modulate cardiac ion channels, suggesting that aldosterone could 
contribute to the electrical disorders observed in HF patients. For example, 
aldosterone was shown to induce the calcium current in rat cardiomyocytes140. 
42 
Regulation of the expression of Nav1.5, the cardiac voltage-gated sodium channel 
Moreover, in mice models of hypo- and hyperaldosteronemia, Perrier and coll.163 
have reported that the blood concentration of aldosterone was modulating the 
calcium current in mouse cardiomyocytes. Finally, the Na-K,ATPase was shown to 
be increased by aldosterone in neonatal rat cardiomyocytes164. 
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Among many ion channels involved in the generation of the cardiac action 
potential, our laboratory focuses on the voltage-gated sodium channel Nav1.5 for its 
crucial role in cardiac cells excitation and conduction. Moreover, numerous cardiac 
diseases have been associated with SCN5A mutations (Nav1.5 gene), including 
congenital long QT syndrome, Brugada syndrome, and conduction disorders165 (see 
Introduction chapter II.2). During my thesis, the cardiac regulation of Nav1.5 was 
investigated along two different axes: 
(1) The regulation of Nav1.5 by the dystrophin multiprotein complex. 
(2) The regulation of Nav1.5 by aldosterone. 
III.1 The regulation of Nav1.5 by the dystrophin 
multiprotein complex 
Recently, an important number of studies have reported the biophysical 
alteration caused by naturally occurring SCN5A mutations2. However in most cases, 
the implication of these mutations on protein-protein interaction in a physiological 
model has not been investigated. A recent study conducted by Mohler et al.166 has 
reported a mutation in Nav1.5 (E1053K) associated with Brugada syndrome that 
blocks ankyrin-G binding and disrupts Nav1.5 cell surface expression. Therefore, the 
proper regulation of the sodium channel by interacting proteins appears to be crucial 
for the cardiac function. In this context, the general aim of my PhD research project 
has been to identify and characterize partner proteins that regulate Nav1.5. This work 
is reported in two articles: 
 
Publication n°1:  
Cardiac Sodium Channel Nav1.5 Is Regulated by a Multiprotein Complex Composed 
of Syntrophins and Dystrophin. 
Gavillet B, Rougier JS, Domenighetti AA, Behar R, Boixel C, Ruchat P, Lehr HA, 
Pedrazzini T, Abriel H. Circulation Research 2006 Aug 18; 99(4):407-14.  
 
47 
III. Aims of the study 
Publication n°2:  
Proteasome inhibitor (MG132) rescues Nav1.5 and the sodium current in 
cardiomyocytes of mdx5cv mice. 
Gavillet B, Rougier JS, Abriel H. In preparation. 
III.2 The regulation of Nav1.5 by aldosterone 
Aldosterone is involved in a variety of pathophysiological processes. In 
particular, aldosterone is increased in patients with heart failure (HF). In addition, 
recent clinical studies have shown that treatment of HF patients with 
mineralocorticoids receptor (MR) antagonists reduced mortality and morbidity142, 143.  
It was therefore suggested that elevated plasma levels of aldosterone 
(hyperaldosteronemia) may have pro-arrhythmogenic properties. Several studies 
have reported that aldosterone could regulate cardiac ion channels. For example, it 
was shown that aldosterone could increase the L-type calcium current (ICa) and 
decrease the transient potassium outward current (Ito)140, 141. It was also shown that 
aldosterone could stimulate the Na-K,ATPase164. In this context we decided to 
investigate the effects of aldosterone on Nav1.5 mediated sodium current. This work 
is reported in the following study: 
  
Publication n°3: 
Aldosterone increases voltage-gated sodium current in ventricular myocytes. 
Boixel C*, Gavillet B*, Rougier JS, Abriel H. American journal of physiology. Heart 
and circulatory physiology 2006 Jun;290(6):H2257-66. Epub 2006 Jan 20. 
*co-first authors 
48 
 IV. Results 
49 

 IV.1 Publication 1 
Cardiac Sodium Channel Nav1.5 Is Regulated by a 
Multiprotein Complex Composed of Syntrophins and 
Dystrophin. 
Gavillet B, Rougier JS, Domenighetti AA, Behar R, Boixel C, Ruchat P, Lehr HA, 
Pedrazzini T, Abriel H. Circulation Research 2006 Aug 18;99(4):407-14. Epub 2006 
Jul 20. 
 
In this study, we investigated the regulation of Nav1.5 by interacting proteins. 
We aimed at identifying proteins binding to the PDZ domain-binding motif formed by 
the last three residues (SIV) of Nav1.5 C-terminus.  
Using biochemical techniques and proteomic tools, we have demonstrated that 
this motif was associated with α and β-syntrophin adapter proteins in order to include 
the sodium channel to the dystrophin multiprotein complex (DMC). To further 
characterize the role of this interaction we used the dystrophin-deficient mdx5cv mice 
model. Our biochemical experiments have revealed that Nav1.5 protein level was 
decreased by ~50% in mdx5cv hearts whereas Nav1.5 mRNA levels were unchanged. 
Patch-clamp experiments indicated that the sodium current was decreased by 29% in 
mdx5cv cardiomyocytes. Finally, ECG measurements of mdx5cv mice showed a 19% 
reduction in the P wave amplitude and an 18% increase in the QRS complex duration. 
Altogether, these results indicate that DMC plays a major role in the regulation 
of Nav1.5.  
 
Contribution to the paper: 
In this study, I entirely carried out the biochemical experiments. After generating 
fusion proteins, I performed pull down experiments demonstrating the interaction 
between Nav1.5 and dystrophin, and I optimized the Western blot quantification 
methodology in order to detect small variations in protein levels. Also, I performed 
mRNA isolations and taqman quantifications, I isolated mouse ventricular myocytes 
used for patch-clamp experiments and finally, I performed part of the ECG 
measurements, although all ECG analyses were conducted by A. Domenighetti. 
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Cardiac Sodium Channel Nav1.5 Is Regulated by a
Multiprotein Complex Composed of Syntrophins
and Dystrophin
Bruno Gavillet, Jean-Se´bastien Rougier, Andrea A. Domenighetti, Romina Behar, Christophe Boixel,
Patrick Ruchat, Hans-Anton Lehr, Thierry Pedrazzini, Hugues Abriel
Abstract—The cardiac sodium channel Nav1.5 plays a key role in cardiac excitability and conduction. The purpose of this
study was to elucidate the role of the PDZ domain-binding motif formed by the last three residues (Ser-Ile-Val) of the
Nav1.5 C-terminus. Pull-down experiments were performed using Nav1.5 C-terminus fusion proteins and human or
mouse heart protein extracts, combined with mass spectrometry analysis. These experiments revealed that the
C-terminus associates with dystrophin, and that this interaction was mediated by alpha- and beta-syntrophin proteins.
Truncation of the PDZ domain-binding motif abolished the interaction. We used dystrophin-deficient mdx5cv mice to
study the role of this protein complex in Nav1.5 function. Western blot experiments revealed a 50% decrease in the
Nav1.5 protein levels in mdx5cv hearts, whereas Nav1.5 mRNA levels were unchanged. Patch-clamp experiments showed
a 29% decrease of sodium current in isolated mdx5cv cardiomyocytes. Finally, ECG measurements of the mdx5cv mice
exhibited a 19% reduction in the P wave amplitude, and an 18% increase of the QRS complex duration, compared with
controls. These results indicate that the dystrophin protein complex is required for the proper expression and function
of Nav1.5. In the absence of dystrophin, decreased sodium current may explain the alterations in cardiac conduction
observed in patients with dystrophinopathies. (Circ Res. 2006;99:407-414.)
Key Words: Duchenne dystrophy  dystrophin  ECG  mouse  sodium channels  syntrophin
The main cardiac voltage-gated sodium channel, Nav1.5,generates the fast depolarization of the cardiac action
potential, and plays a key role in cardiac conduction. Its
importance for normal cardiac function has been exemplified
by the description of numerous naturally occurring genetic
variants of the gene SCN5A, which encodes Nav1.5, that are
linked to various cardiac diseases.1 Among them, the congen-
ital long QT syndrome type-3 and the Brugada syndrome are
caused by gain or loss-of-function of Nav1.5, respectively.1
Nav1.5 is the pore-forming -subunit protein of the cardiac
sodium channel. It has a molecular weight of 220 kDa, and
may be associated with at least 4 types of auxiliary small (30
to 35 kDa) -subunits. Recently, several proteins that bind
directly to Nav1.5 have been described.2 However, in most
cases the physiological relevance of these interactions re-
mains poorly understood, mainly because of a lack of
appropriate animal models. With the exception of ankyrin-G,3
all these partner proteins interact with the 243-residues-long
intracellular C-terminal domain of the channel which con-
tains several protein-protein interaction motifs.2 Among
them, the last three residues of Nav1.5 (2014-Ser-Ile-Val-
2016) constitute a PDZ domain-binding motif to which
syntrophins and dystrophin have been shown to interact
directly or indirectly, respectively.4–6 However, thus far, the
role of these interacting proteins in the heart has never been
investigated.
In this study, by performing mass spectrometry-based
protein identification using human and rodent cardiac lysates,
we could confirm that dystrophin and syntrophin proteins are
interacting specifically with the PDZ domain-binding motif
of Nav1.5. Biochemical and electrophysiological studies us-
ing cardiac tissue and cells of dystrophin-deficient mdx5cv
mice (an animal model of Duchenne muscular dystrophy
[DMD]) revealed that Nav1.5 protein content as well as
Nav1.5-mediated current (INa) were decreased in the absence
of dystrophin. Finally, ECGs of mdx5cv mice showed alter-
ations characteristic of conduction defects. These findings
suggest that Nav1.5 is part of a multiprotein complex in which
dystrophin and syntrophin proteins play an important role in
its expression level. Moreover, these results provide the
pathophysiological basis for some of the ECG abnormalities
seen in DMD patients, and other dystrophinopathy patients,
in whom cardiac arrhythmias and conduction defects may
lead to sudden death.7
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Materials and Methods
An expanded Materials and Methods section is available in the
online data supplement at http://circres.ahajournals.org.
Animals
Wild-type C57BL/6 mice, used as control, were purchased at Janvier
(Le Genest St Isle, France), and C57BL/6Ros-5Cv (mdx5cv) mice
(Jackson laboratories, Bar Harbor, Me) were raised in our depart-
ment. Male mice at an age of 10 to 14 weeks were used in this study.
All animal procedures were performed in accordance with the
Swiss laws.
Cardiac Tissue Samples
The experimental procedures were approved by the ethical commis-
sion on clinical research of the faculty of medicine of the University
of Lausanne. Human right atrial sample was collected from patients
in normal sinus rhythm undergoing coronary bypass surgery. Mice
were anesthetized and heart ventricles were excised, rinsed with ice
cold PBS and frozen in liquid nitrogen. Fresh human atrial append-
age or frozen mouse ventricle was transferred into lysis buffer.
Tissues were then homogenized using a Polytron and a Teflon
homogenizer. Triton Tx-100 was added to a final concentration of
1% and solubilization occurred by rotating for 1 hour at 4°C. The
soluble fraction from a subsequent 15-minute centrifugation at
13 000g (4°C) was used for the experiments.
Mass Spectrometry Peptide Analysis
SDS-PAGE gels were stained with SYPRO dye (Molecular Probes,
Eugene, Ore). The gel was visualized on a UV-light transilluminator.
The bands of interest were excised and sent to the Protein Analysis
Facility of Lausanne where they were submitted to trypsin digestion,
liquid chromatography and tandem mass spectrometry.
Pull-Down Assays
The cDNAs encoding the 66 last amino acids of Nav1.5 WT,
Y1977A, and S2014Stop were cloned into pGEX-4T1 (Amersham
Bioscience, Piscataway, NJ). GST-fusion proteins were obtained
using Escherichia coli. GST-pull-down assays of soluble fractions of
ventricular lysate were performed using GSH-sepharose beads con-
taining either GST or the GST fusion proteins. After 2-hour rotation
and washing, bound proteins were detected by Western blot.
Western Blot and Antibodies
Western blotting conditions and the specificity of the polyclonal
Nav1.5 antibody (ASC-005; Alomone) has been previously de-
scribed.9 A control Western blot using the peptide antigen showing
the specificity of the signal is presented in the online data supple-
ment. The polyclonal antibody Kir2.1 (APC-026) was purchased
from Alomone (Jerusalem, Israel). Polyclonal connexin-43 antibody
(71-0700) was obtained from Zymed (San Francisco, Calif). Mono-
clonal dystrophin antibody (MANDYS8) was from SIGMA (Buchs,
Switzerland). Monoclonal pan-syntrophin antibody (MA1–745) was
purchased from Affinity Bioreagents (Golden, USA). Polyclonal
1-, 1-, and 2-syntrophin antibodies were kindly provided by M.
Schaub (University of Zurich), and 1- and  2-syntrophin antibod-
ies were from Santa Cruz Biotechnology (Santa Cruz, Calif).
Polyclonal Cav1.2 antibody was a gift from J. Hell (University of
Iowa), Na,K-ATPase antibody was a gift from K. Geering (Univer-
sity of Lausanne) and Nedd4–2 antibody was a gift from O. Staub
(University of Lausanne).
TaqMan Real-Time Reverse-Transcription
Polymerase Chain Reaction
Total RNA was extracted from whole ventricles according to
described protocol in.9 cDNA was synthesized from 1 g of total
RNA using the MU-MLV reverse transcriptase (Q-Biogene
EMMLV100; Irvine, Calif). Fifty nanograms of cDNA combined
with 1 TaqMan Universal Master Mix (Applied Biosystems,
Foster) and 1 L of either Nav1.5, Kir2.1 or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe (Applied Biosystems,
respectively, Mm00451971, Mm00434616 and Mm99999915) were
loaded into each well. GAPDH was used as reference gene for
normalizing the data.
Isolation of Cardiac Myocytes and
Patch-Clamp Experiments
Adult mouse ventricular myocytes were isolated as described.9
Whole-cell configuration of the patch-clamp technique was used to
record INa. Experiments were performed at room temperature (22°C
to 23°C), using a VE-2 (Alembic Instruments) amplifier allowing the
recording of large sodium currents.9 Pipettes (tip resistance 1 to 2
M) were filled with a solution containing 60 mmol/L aspartic acid,
70 mmol/L cesium asparte, 1 mmol/L CaCl2, 1 mmol/L MgCl2,
10 mmol/L HEPES, 11 mmol/L EGTA, and 5 mmol/L Na2ATP (pH
was adjusted to 7.2 with CsOH). Myocytes were bathed with a
solution containing 10 mmol/L NaCl, 120 mmol/L NMDG-Cl,
2 mmol/L CaCl2, 1.2 mmol/L MgCl2, 5 mmol/L CsCl, 10 mmol/L
HEPES, and 5 mmol/L Glucose (pH was adjusted to 7.4 with CsOH).
ECG
The mouse ECG was recorded as previously described.10 Corrected
QT interval (QTc) was calculated according to Mitchell et al11:
QTcQT/(RR/100)1/2.
Histology and Image Analysis
Four-M sections through the subvalvular plane of formaldehyde-
fixed paraffin-embedded hearts were prepared and stained with
Elastica van Gieson stain according to standard protocols. Three
representative 20 fields were photographed, using an digital
camera, from the subendocardial, central, and subepicardial region of
the left ventricle and imported into Photoshop (version 7.0; Adobe
systems Inc). Using the magic wand tool and the select similar
command, all dark-stained nuclei were selected and their surface
quantified by the histogram tool (given in pixel per inch, and then
translated into m2 according to the total magnification of the
image). The mean nuclei size was calculated by the division of the
total nuclear area by the number of nuclei as counted using a
commercially available plug-in (count marks, The image processing
toolkit; Reindeer Games, Charlotte, NC) and given in m2. In the
absence of notable tissue fibrosis, edema, or prominent intra-
myocardic vessels, the cytoplasmic area was calculated as the total
area of the 20 field minus the nuclear area (see above) then divided
by the number of nuclei assessed as described.
Statistical Analyses
Data are represented as mean valuesSEM. Two-tailed Student t test
was used to compare means. Statistical significance was set at
P0.05.
Results
C-Terminal Domain of Nav1.5 Interacts With
Dystrophin and Syntrophin Proteins
Recently, several proteins have been described to interact
with specific protein-protein interaction motifs of the
C-terminal domain of Nav1.5.2 Using a mass spectrometry-
based approach with GST-fusion proteins of the last 66
residues of Nav1.5 C-terminus (Figure 1A), we searched for
proteins extracted from human right atrial appendage samples
interacting specifically with the PDZ domain-binding consen-
sus motif formed by the last three Ser-Ile-Val (SIV) amino
acids.4 The SDS-page presented in Figure 1B shows a
high-molecular-weight protein that was reproducibly pulled
down using the WT fusion protein, but not with a protein
lacking the SIV residues (SIV). This protein was identified
as dystrophin in human atrial samples (Table 1) as well as in
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mouse and guinea pig ventricular samples, with a high degree
of confidence. Because dystrophin is known to frequently
interact with partner proteins via syntrophin adapter pro-
teins,12 we performed an additional experiment in which we
examined by mass spectrometry the 50 to 60 kDa region of
the WT lane of the gel: both 1- and 1-syntrophin proteins
were identified with high confidence based on the numbers of
peptidic fragments (Table 1). To better understand the mo-
lecular features of this multiprotein complex that binds to the
C-terminal domain of Nav1.5, we performed Western blot
analyses of the pulled-down proteins. As a control tissue we
used ventricular lysates of dystrophin-deficient mdx5cv mice.8
In this set of experiments, we also performed pull-down
experiments using a fusion protein in which the Nav1.5
PY-motif was mutated (Y1977A; Figure 1A) because this
motif is known to interact with WW-domains similar to the
one present in dystrophin.13 However, as depicted in Figure
1C, dystrophin also interacted with the PY-motif mutated
protein, indicating that this motif is not likely to play a key
role in the interaction of dystrophin with Nav1.5. Moreover, it
is also apparent that neither dystrophin nor syntrophin pro-
teins bind to the SIV-truncated protein (Figure 1C). The
endogenous mouse ubiquitin-protein ligase Nedd4–2, previ-
ously shown to bind to the PY-motif of Nav1.513 was
pulled-down with the WT and the SIV-truncated fusion
proteins, which attests for the integrity of the SIV-truncated
protein (Figure 1C). Using isoform-specific antibodies recog-
nizing 1-, 1-, and 2-syntrophin proteins, we found that all
three were pulled-down with the WT Nav1.5 C terminus
fusion protein. We also tested two antibodies recognizing 1-
and 2-syntrophin, but these two proteins could not be
detected in the mouse cardiac lysates (not shown).
Nav1.5 Protein Is Specifically Decreased in mdx5cv
Cardiac Tissue
We then performed Western blot experiments using ventric-
ular lysates of mdx5cv and control mice to study the conse-
quences of the dystrophin deficiency on Nav1.5 protein level.
Figure 2A illustrates that when dystrophin was absent, a
consistent reduction of the Nav1.5 protein level was detected
in four mdx5cv mouse hearts. This phenomenon was specific
for Nav1.5 because we did not observe any other obvious
decrease in protein levels of major membrane proteins such
as the L-type Ca2 channel (Cav1.2), connexin-43, and
-subunit of the Na-K,ATPase. The protein levels of several
heart extracts were quantified by digital densitometry, and
Figure 2B shows that the Nav1.5 content was decreased by
509% in mdx5cv hearts compared with controls. With the
exception of a small, albeit statistically significant, 144%
decrease in the level of Kir2.1 in mdx5cv hearts, the expression
of all other tested proteins was not altered in the absence of
dystrophin. It could have been hypothesized that this decrease
in Nav1.5 amount in mdx5cv hearts may have been caused by
a reduction of the SCN5A mRNA level. However, this was
not the case because quantitative RT-PCR experiments using
a SCN5A TaqMan probe did not reveal any difference
between control and mdx5cv hearts (Figure 2C). Similarly, the
mean mRNA level of Kir2.1 was not modified in mdx5cv
hearts. Thus, the decreased Nav1.5 content may be attribut-
able to either a reduced translation rate or increased turnover
of the channel protein in the absence of dystrophin.
Sodium Current Is Decreased in
mdx5cv Cardiomyocytes
To investigate whether the decrease of the total cardiac
Nav1.5 protein amount seen in mdx5cv hearts alters the cellular
sodium current (INa), we performed patch-clamp experiments
using freshly isolated ventricular myocytes in the whole-cell
configuration. Peak INa density was reduced by 292% in
mdx5cv myocytes compared with control cells (Figure 3A,
3B). This INa reduction was not caused by alterations of the
voltage-dependence of either steady-state activation or inac-
Figure 1. Binding of dystrophin and syntrophin proteins to
Nav1.5 C-terminus. A, Schematic representation of the four
fusion proteins used for the pull-down experiments described in
(B) and (C) comprising the last 66 amino acids of Nav1.5 with
the PY-motif (PPxY) and PDZ domain-binding motif (SIV). SIV
corresponds to the last 66 amino acids carrying the S2014stop
mutation, and YA, to the last 66 amino acids with the Y1977A
mutation. B, Pull-down experiment realized by incubating the
soluble fractions of a human atrial appendage lysate with GSH-
Sepharose beads containing either the GST protein alone (GST)
or with two Nav1.5 GST fusion proteins: WT and SIV. Pulled-
down fractions and 80 g of appendage lysate (input) were
loaded on a SDS-page gel, which was stained using the Sypro
dye. The arrow indicates a band at high molecular weight only
present in the fraction pulled-down with the WT fusion protein.
This band was excised, analyzed by mass spectrometry and
identified as being dystrophin (Table 1). C, Western blots of
pulled-down fractions performed on mouse ventricular lysate of
either control or mdx5cv mice as indicated. Mouse ventricular
lysates were mixed with GSH-Sepharose beads containing
either the GST protein alone (GST) or with three Nav1.5 GST
fusion proteins: WT, YA, or SIV. Eighty g of control and
mdx5cv ventricular lysate were loaded in the input lane. SIV
fusion protein is able to bind Nedd4–2, which is a protein
known to interact with the Nav1.5 PY-motif. The bottom panel is
a Ponceau staining of a representative nitrocellulose membrane
indicating that similar amount of GST and GST fusion proteins
were used for the different pull-downs.
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tivation, as illustrated in Figure 3C. Moreover, cell size was
not different, as assessed by measuring the electrical capac-
itance (control cells 1497 pF and mdx5cv 1579 pF, not
significant, n17 and 17 cells, respectively).
ECGs of mdx5cv Mice Reveal Conduction Defects
Subsequently, we investigated the consequences of this al-
tered cellular excitability on surface ECGs of control and
mdx5cv mice. Figure 4 shows representative ECG recordings
(leads I, II, and III) of one control and two mdx5cv mice. The
mdx5cv ECGs were characterized by a significant prolongation
of the QRS complex (185%), a decrease of the P wave
amplitude (	196%), and a trend, albeit not significant, to
prolonged P wave duration (Table 2). These findings point
toward both intra-atrial and intra-ventricular conduction de-
fects. Note that the heart rate and ventricular repolarization,
reflected on the mouse ECG by the ST interval (similar, but
not equivalent, to the JT interval in humans) were not
different between mdx5cv and control mice (Table 2).
Mdx5cv Cardiac Tissues Do Not Show any Sign of
Fibrosis or Cellular Hypertrophy
Because the intra-ventricular conduction defects may also
have been caused by fibrosis of the mdx5cv ventricular
myocardium, a phenomenon described in older mdx mice,14
we (H.A.L.) analyzed, in a blinded fashion, ventricular
sections that were prepared with an elastic van Gieson stain.
However, there was no increase in interstitial fibrosis neither
in mdx5cv nor in control mice (n4 animals of each group). In
addition, we did not find any difference in nuclear and/or
cytoplasmic size that may have reflected cardiac hypertrophy
(not shown).
Discussion
The principal findings of this study are: (1) that cardiac
dystrophin and syntrophin proteins are partners of the main
cardiac voltage-gated sodium channel Nav1.5, and that this
interaction depends exclusively on the C-terminal PDZ
domain-binding motif of Nav1.5; (2) that Nav1.5 protein level
is reduced in ventricles of dystrophin-deficient mdx5cv mice
TABLE 1. Proteins Pulled-Down Using Nav1.5 WT Fusion Protein and Identified by Mass Spectrometry
Protein Other Names Score
Calculated
Molecular Mass
Amino Acids
Position Peptide Sequence Matches
DMD Human Dystrophin 239 428.46 50–61 LLDLLEGLTGQK
738–751 SEAVLQSPEFAIFR
783–802 SAQALVEQMVNEGVNADSIK
2524–2538 RPQLEELITAAQNLK
2690–2700 LLQQFPLDLEK
2871–2883 IFLTEQPLEGLEK
2936–3949 LQELQEATDELDLK
DMD Mouse Dystrophin 467 427.66 450–458 VLMDLQNQK
715–723 QITVDSELR
785–804 SAQALVEQMANEGVNAESIR
882–893 LSALQPQIEQLK
1494–1512 SVEQEVIQSQLSHCVNLYK
1754–1764 VVEPQISELNR
1960–1969 QIESNFAQFR
2045–2053 DNLQQISGR
2149–2157 ELQDGIGQR
2255–2263 LLAEELPLR
2670–2682 VSEQEAALEETHR
2758–2770 SLEGSDEAPLLQR
2850–2863 TKEPVIMSTLETVR
3019–3027 LLQVAVEDR
3227–3239 LGLLLHDSIQIPR
3502–3511 ILADLEEENR
Mouse -1 SYN -1 Syntrophin 156 54.08 86–97 KADAGGLGISIK
354–367 GSVPYDAELSFALR
372–392 HGVDTHLFSVESPQELAAWTR
483–495 TMVFIIHSFLSAK
Mouse -1 SYN -1 Syntrophin 51 58.44 117–127 QELGGLGISIK
The score is calculated using the Mowse scoring algorithm.40 The identified proteins are displayed along with matching peptide
sequences. The first row corresponds to the human atrial sample, and the last three rows correspond to the mouse ventricle sample.
410 Circulation Research August 18, 2006
56
(an animal model of DMD); and (3) that this reduced
expression of Nav1.5 mdx5cv mice leads to decreased cellular
sodium current and conduction defects that could be docu-
mented by surface ECGs.
Description of the Protein Complex
Previous studies have already reported that Nav1.5 interacts
with syntrophin proteins.4,5 In the present study, we went one
step further and characterized this complex by showing that
this interaction with syntrophins depends largely on the PDZ
domain-binding motif, and that a direct dystrophin-Nav1.5
interaction via the PY-motif of Nav1.5 was unlikely. We also
translated this concept into the human situation by reproduc-
ing it on human heart protein extracts. Moreover, we obtained
evidence suggesting that 1-, 1-, and 2-syntrophins are
likely to be the bona fide cardiac partners of Nav1.5, because,
in analogy to findings of Iwata et al,15 -syntrophin proteins
were not detected in cardiac lysates. Several other ion
channels bearing a PDZ domain-binding motif have been
reported to be part of the dystrophin protein complex (DPC)
located at the plasma membrane of different cell types.
Among them, the Kir2.x channels are expressed in cardiac
cells,16 Nav1.44,17 and aquaporin-418 are expressed in the
skeletal muscle, and Kir4.1 has been localized to glial cells.19
Our present studies have for the first time investigated
pathological cardiac phenotypes related to altered function of
these channels using the model of mdx mice.
Colocalization of Dystrophin and Nav1.5
Cardiac Nav1.5 channels are localized at the intercalated disk
regions of cardiomyoctes,3,20 as well as in the lateral mem-
branes.3,21–23 However, dystrophin has been shown to be
absent from the intercalated discs of human24 and rat25
cardiac cells. These findings, in conjunction with the present
results, suggest that at least two distinct pools of Nav1.5
channels co-exist in the plasma membrane of cardiac myo-
Figure 2. Nav1.5 protein level is specifically reduced in mdx5cv
mice heart lysates. To quantify the amounts of Nav1.5, Cav1.2,
Kir2.1, Na,K-ATPase and connexin-43 present in the heart of
control and mdx5cv mice, 80 g of ventricular lysates were
loaded on SDS-page gels. Protein concentration of each lysate
was measured in triplicate by Bradford assay to guarantee
equivalent loading. Western blots were performed with various
antibodies as indicated, and the amounts of protein were quan-
tified by digital densitometry for each mouse. A, Representative
Western blots for each antibody used. Three to four similar
Western blots were used for quantification in Figure 2B. B, Bar
graph quantifying the amount of Nav1.5, Cav1.2, Kir2.1, Na,K-
ATPase and connexin-43 detected in the ventricular lysate of
control and mdx5cv mice. The number of mice used for quantifi-
cation is indicated in the bars. Results are expressed as normal-
ized mean signal intensity. *P0.05. **P0.001. n.s.not signifi-
cant. C, Quantitative reverse-transcription polymerase chain
reaction experiments. Bar graph representing the amounts of
Nav1.5 and Kir2.1 mRNA in control and mdx5cv ventricles, ana-
lyzed by TaqMan as described in Material and Methods.
Figure 3. INa is decreased in mdx5cv cardiomyocytes. A, Repre-
sentative current traces recorded from control and mdx5cv mice
cardiomyocytes. B, Normalized current density-voltage relation-
ship of INa in control and in mdx5cv mice. The protocol is indi-
cated in inset, and the number of cells is indicated next to the
symbols. *P0.05. **P0.01 compared with control. C, Steady-
state inactivation and activation curves from control and mdx5cv
mice cardiomyocytes. Boltzmann curves of individual cells were
fitted to steady-state activation data: control V1/2	38.31.3
mV, K4.90.5; mdx5cv V1/2	37.31.1 mV, K5.00.2. The
voltage-dependence of steady-state inactivation parameters
were: control V1/2	76.21.2 mV, K5.30.3; mdx5cv
V1/2	75.30.8 mV, K5.70.2. The differences between the
groups were statistically not significant. The protocol is indi-
cated in inset, and the number of cells is indicated next to the
symbols.
Gavillet et al Nav1.5 Function Is Regulated by Dystrophin 411
57
cytes. One pool, belonging to the DPC, may be localized in
lateral membranes, whereas another pool could reside in the
intercalated disks. In the latter compartment, the PDZ
domain-binding motif of Nav1.5 may be associated to another
protein complex that remains to be characterized.
Interestingly, Baba et al22 recently described that dog
cardiomyocytes isolated from infarcted zones displayed a
reduced INa density (
50%), along with a specific and marked
loss of the lateral membrane Nav1.5 staining. In contrast, in
the intercalated disk area, the Nav1.5 staining remained
unchanged. It is intriguing to speculate whether dystrophin is
involved in this phenomenon. Moreover, if this “two Nav1.5
pools” hypothesis is correct, the study of Baba et al,22 in
conjunction with our results, would support the importance of
these sodium channels in lateral membranes in the conduction
of the cardiac impulse.
Is Decreased Expression Level of Channel Proteins
a General Phenomenon?
Dystrophin is a large protein that exerts multiple roles. Its
absence leads to a reduced expression of DPC proteins in
skeletal muscle26 and cardiac tissue.27 In skeletal muscle of
mdx mice, the expression of Nav1.417 and aquaporin-418 are
significantly reduced. In our animal model, a small reduction
of Kir2.1 was also observed. The relevance of this phenome-
non is most likely marginal since no repolarization abnormal-
ity on the ECG was observed. In analogy to our present
findings, the reduced protein expression was not attributable
to decreased mRNA levels.17,18 In contrast, it should be noted
that Nav channel expression in spermatozoa has been shown
to be increased when dystrophin is absent.28 Furthermore, in
1-syntrophin-deficient mice, the abundance of Nav channels
at the neuromuscular junction was not modified, whereas
their localization was altered.29 Altogether, these findings
suggest that one of the possible roles of dystrophin is to
stabilize specific ion channel proteins by unknown mecha-
nisms (similarly to the other DPC proteins) in the plasma
membrane. Whether dystrophin may be important for the
trafficking, anchoring, regulation of ion channel protein
turnover, or other phenomena remains to be further studied.
ECG Alterations Are Consistent With
Previous Studies
In mdx5cv mice, the QRS complex duration, reflecting intra-
ventricular conduction, was prolonged by 18%. These data
compare to 39% increase in QRS duration in 10-week-old
mice expressing only one SCN5A allele,30 where cellular INa is
reduced to 50% of control mice.31 These QRS prolongation
values are in good agreement with the estimate that can be
inferred from the data of Shaw and Rudy32 where a reduction
of INa by 29% (this study) or 50%30 would lead to a
prolongation in duration for a given distance of 18% and
33%, respectively. Furthermore, the intra-atrial conduction
defects seen in mdx5cv mice in our present study are consistent
with corresponding alterations reported in the studies men-
tioned above.30,31 Because connexin-43 levels are not altered,
and in the absence of fibrosis, we propose that the cardiac
electrical phenotype of mdx5cv mice is a “pure” conduction
defect secondary to the reduction in Nav1.5 protein level in
absence of dystrophin. Whereas these considerations pertain
to young (10 to 12-week old) mdx5cv mice, it is well possible
that older mice go onto develop a more complex cardiac
phenotype with fibro-fatty degenerative features.
Relevance for the Human
Cardiac Dystrophinopathies
DMD and Becker patients frequently show cardiac manifes-
tations secondary to the absence of dystrophin in cardiac
tissue. Many of these patients display dilated cardiomyopathy
and heart failure.7 In addition, ECG abnormalities can also be
detected in up to 60% of 10-year-old DMD patients,7 and
Figure 4. Mdx5cv mice exhibit ECG alterations. ECG traces, from
classical leads I, II, and III, measured in one control and two
different mdx5cv mice. Note the visible widening and alterations
of the QRS complexes of the two mdx5cv mice. The averaged
ECG parameters are presented in Table 2.
TABLE 2. ECG Characteristics of Control and mdx5cv Mice in Lead I
n RR (ms) Pdur (ms) Pamp (V) PR (ms) QRS (ms) QT (ms) QTc (ms) ST (ms)
Control 12 1414 11.70.28 863 50.52.48 14.20.28 57.21.13 48.51.20 43.31.19
mdx5cv 13 1394 12.40.37 705 47.21.43 16.70.69 58.31.11 49.61.12 41.60.84
P ns ns 0.05 ns 0.005 ns ns ns
RR indicates RR interval duration; Pdur, P-wave duration; Pamp, P-wave amplitude; PR, PR interval duration, QRS, QRS-complex duration; QT, QT interval duration;
QTc, corrected QT interval duration; n.s., not significant. Data are expressed as meanSEM.
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among those, conduction defects are frequent.33 Indeed,
life-threatening arrhythmia can cause sudden death in these
dystrophinopathy patients.34 The relevance of early func-
tional defects involving Nav1.5 in mdx5cv mice on the genesis
of cardiac dysfunction in DMD patients is a matter of
speculation. Two recent studies have reported that loss-of-
function mutations in SCN5A may cause dilated cardiomyop-
athy35,36 in humans. Whether reduced INa may lead to myo-
cardial degeneration in dystrophinopathies, dilated
cardiomyopathies,35,36 or the Brugada syndrome, as recently
described,37 remains to be shown. In addition, based on the
findings of this study, it could be proposed that genes
encoding proteins of the DPC complex, in particular syntro-
phin proteins, should be screened in patients with Brugada
syndrome, because it may be foreseen that absence or
loss-of-function of syntrophins may also lead to a reduced
function of Nav1.5. Interestingly, a recent abstract38 indicated
that mutations in the caveolin-3 gene, a protein that is also
part of the DPC,39 may lead to congenital long QT syndrome
by altering the function of Nav1.5. This finding supports well
the model of Nav1.5 being part of the dystrophin multiprotein
complex.
Conclusions
In summary, our work provides evidence that at least one
fraction of the Nav1.5 channels is part of the dystrophin
protein complex in cardiomyocytes. Absence of dystrophin in
young mdx5cv mice leads to reduced Nav1.5 levels and hence
reduced INa, associated with cardiac conduction defects.
Whether these early functional defects may underlie the more
severe morphological and mechanical alterations seen in
dystrophinopathy patients warrants further investigation.
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 IV.2 Publication 2 
Proteasome inhibitor (MG132) rescues Nav1.5 and 
the sodium current in cardiomyocytes of mdx5cv 
mice.   
Gavillet B, Rougier JS, Abriel H. In preparation. 
 
In this study we investigated the mechanisms underlying the dysregulation of 
Nav1.5 previously described in mdx5cv mice. To investigate the implication of the 
ubiquitin proteasome system (UPS) in the observed phenomenon, we treated mdx5cv 
mice with proteasome inhibitor (MG132) delivered by osmotic pumps.  
Biochemical and patch-clamp experiments indicated that Nav1.5 protein level 
and the sodium current were rescued in mdx5cv mice treated with MG132 whereas 
Nav1.5 mRNA levels remained unchanged. Noteworthy, dystrophin protein 
expression was not rescued in skeletal or cardiac muscle of mdx5cv mice. Finally, 
performing pull-down experiments using S5a fusion proteins, we showed that Nav1.5 
ubiquitylation level was decreased in mice treated with MG132. Altogether our results 
indicate that the UPS is implicated in the dysregulation of Nav1.5 observed in mdx5cv 
mice, however the regulation mechanism remains unclear. This study is the first to 
report variations in the ubiquitylation of ion channels in vivo. 
 
Note: For the coherence of the thesis report, the preliminary results are 
presented as a manuscript in preparation. For this study to be accepted in a scientific 
journal, the interpretations need to be reinforced by additional experiments.   
 
Contribution to the paper: 
I performed all the experiments presented in this manuscript except patch-
clamp experiments presented in Figure 1B.  
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Abstract 
The cardiac sodium channel Nav1.5, which plays a central role in cardiac 
excitation and conduction, associates with the dystrophin multiprotein complex 
(DMC)1. We previously showed that Nav1.5 protein content and INa were decreased 
in cardiomyocytes of dystrophin-deficient mdx5cv mice2. In this study, we implanted 
osmotic minipumps delivering proteasome inhibitor MG132 (10 µg/Kg/24 h). We 
found that treatment of mdx5cv mice with MG132 led to a rescue of both the total 
amount of Nav1.5 protein and the sodium current (INa) but unlike Bonuccelli and 
coworkers3, we did not detect expression of dystrophin in skeletal and cardiac 
muscle. Finally, our results suggested that the ubiquitylation level of Nav1.5 was 
increased in mdx5cv mice and that MG132 treatment was associated with a decrease 
of the ubiquitylation of the sodium channel. The present study provides new elements 
to our understanding of the interaction between the sodium channel and DMC. 
Moreover, these new findings may have clinical implications for the treatment of 
some of the cardiac alterations observed in patients with dystrophinopathies. 
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Introduction 
The cardiac voltage-gated sodium channel Nav1.5 plays a central role in heart 
function since it is responsible for the depolarization of the cardiac action potential 
and myocardial conduction. Mutations in the sodium channel gene (SCN5A) are 
detected in an important number of cardiac diseases such as the congenital long QT 
syndrome and the Brugada syndrome. A recent study has also reported a mutation of 
Nav1.5 associated with dilated cardiomyopathy4-8. However, despite many studies 
aiming at characterizing naturally occurring SCN5A mutations little is known about 
the regulation of the cardiac sodium channel. Recent studies reporting Nav1.5 
interacting partners suggest that the sodium channel is part of multiprotein 
complexes that may differ between one cellular compartment to another, and that 
could be involved in the regulation of channel activity, cellular localization or in 
protein degradation9-11. Given the important role played by Nav1.5 in cardiac function, 
alterations of these regulatory mechanisms could be the cause of cardiac diseases 
for which the mutated gene is still unidentified (e.g. only 20% of the Brugada 
syndrome cases are associated with SCN5A mutation)12.  
Among the interacting proteins, we2 and others1 have reported that Nav1.5 is 
associated to the dystrophin multiprotein complex (DMC) in the heart.  Dystrophin is 
a ~430 kDa cytoplasmic protein which associates with a protein complex at the 
plasma membrane13. In muscle cells, the DMC is thought to strengthen the 
sarcolemma during contraction by providing a link between the extracellular matrix 
and the cytoskeleton. Mutations in the dystrophin gene result in Duchenne and 
Becker muscular dystrophies (DMD and BMD), as well as X-linked dilated 
cardiomyopathy (XLDCM). Using the mdx5cv (dystrophin-deficient) mouse model, we 
recently showed that the absence of dystrophin in cardiomyocytes leads to a ~50% 
decrease in the total amount of Nav1.5 protein associated with a decrease of a ~30% 
in the cellular sodium current. In addition, ECG measurements revealed atrial and 
ventricular conduction slowing consistent with a ~30% reduction of the sodium 
current (INa).  
Previous studies from our group11 have shown that Nav1.5 is ubiquitylated in 
mouse cardiac tissue, and that the sodium channel can be ubiquitylated by Nedd4 
ubiquitin ligases in HEK293 cells. In this study we aimed at elucidating the implication 
of the ubiquitin proteasome system (UPS) in the regulation of Nav1.5.  
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For this purpose, we treated control and dystrophin-deficient mdx5cv mice with 
proteasome inhibitor MG132 delivered by osmotic minipumps at a dose of 10 
µg/Kg/24 h. Our results indicate that (1) MG132 treatment rescues Nav1.5 expression 
and the sodium current in cardiomyocytes of mdx5cv mice; (2) proteasome inhibition 
does not restore dystrophin expression in skeletal or cardiac muscle of mdx5cv mice; 
and (3) the ubiquitylation level of Nav1.5 is increased in mdx5cv mice under control 
conditions and decreased upon MG132 treatment.  
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Materials and Methods 
Animals 
Wild type C57BL/6 mice, used as control, were purchased at Janvier (Le Genest St Isle, France), and 
C57BL/6Ros-5Cv (mdx5cv) mice (Jackson laboratories, Bar Harbor, Maine), were raised in our 
department. Male mice at an age of 12-16 weeks were used in this study. All animal procedures were 
performed in accordance with the Swiss laws. 
Minipumps 
Osmotic minipumps (ALZET model 1007D, Alzet Osmotic Pump Company, Cupertino, USA) were 
subcutaneously implanted in the anterior back region of the mice. Pumps were filled up with either a 
MG132 solution or with the vehicle alone according to ALZET filling procedure. MG132 (C2211, 
SIGMA, Buchs, Switzerland) was delivered at a dose of 10 µg/Kg/24 h, 2 mM MG132 aliquot were 
prepared in dimethylsulfoxide (Merck, Damstadt, germany)  before being further diluted to the 
appropriate concentration in 0.9% NaCl.  
Mice ventricular myocyte isolation 
Seven days after implantation of the osmotic pump, mice were anesthetized by intraperitoneal 
injection of 100 μl of pentobarbital (50 mg/ml) and 100 μl of heparin (Liquemin 5000 U.I./ml, Roche, 
Basel, Switzerland), the hearts were excised, rinsed in Krebs solution,  mounted on a Langendorff 
apparatus and subjected to collagenase retroperfusion. The procedure for mice ventricular myocyte 
isolation has been previously described in details2. About 10% of isolated myocytes were plated on 
laminin coated dish and used for patch clamp measurements, the remaining myocytes were frozen as 
a pellet. Frozen pellets were subsequently used for mRNA or protein extraction. 
Protein extraction 
Gastrocnemial muscle were removed, washed with ice cold PBS and frozen in liquid nitrogen. Frozen 
myocytes or skeletal muscles were transferred into lysis buffer (50 mM TRIS pH 7.5, 150 mM NaCl, 1 
mM EDTA, 1 mM PMSF and Complete® protease inhibitor cocktail from Roche). Tissues were then 
homogenized using a Polytron, Triton Tx-100 was added to a final concentration of 1% and 
solubilization occurred by rotating for 1h at 4°C. The soluble fraction from a subsequent 15-min 
centrifugation at 13,000 g (4°C) was used for the experiments. In order to load each lane of the SDS-
page with equivalent amounts of total proteins, the protein concentration of each lysate was measured 
in triplicate by Bradford assay using a BSA standard curve. 
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S5a Pull-down assays 
Following MG132 systemic treatment, mice were anesthetized, the hearts were excised, rinsed with 
ice cold PBS and frozen in liquid nitrogen. Frozen ventricles were transferred into lysis buffer (50 mM 
TRIS pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 10 mmol/L N-ethlylmaleimide , 1 mM 1,4-
dithiothreitol, 100 mM NaF, 10 mM Na-pyrophosphate and Complete® protease inhibitor cocktail from 
Roche). Hearts were homogenized using a Polytron, Triton Tx-100 was added to a final concentration 
of 1% and solubilization occurred by rotating for 1h at 4°C. The soluble fraction from a subsequent 15-
min centrifugation at 13,000 g (4°C) was used for the pull-down assay. GST-fusion protein of the 
ubiquitin-binding proteasomal subunit S5a (GST-S5a) was obtained from a pGEX construct kindly 
provided by Dr R. Layfield (University of Nottingham, UK). GST-fusion proteins were produced in 
E.coli. GST-pull-down assays were performed on the soluble fractions of ventricular lysates using 
GSH-sepharose beads containing either GST or the GST-S5a fusion protein. Following 2 h rotation 
and washing, bound proteins were detected by Western blot. 
Western blots 
Western blotting conditions have been previously described2. The polyclonal dystrophin antibody 
directed against the protein N-terminus (Dys12) was kindly provided by M. Schaub (University of 
Zurich). The monoclonal dystrophin antibody (MANDYS8) and polyclonal actin antibody (A2066) were 
from SIGMA. The polyclonal Nav1.5 antibody (ASC-005) was purchased from Alomone (Jerusalem, 
Israel). Two anti-ubiquitin monoclonal antibodies were used: FK2 (Biomol International, Exeter, UK) 
and Ubi.1 (Zymed Laboratories, San Francisco, USA).  
Mice ventricular myocyte mRNA extraction 
RNA was extracted from frozen myocytes using the RNeasy Mini Kit, according to the manufacturer 
protocol (Qiagen, Hombrechtikon, Switzerland). cDNA was synthesized from 1 µg of RNA using the 
MU-MLV reverse transcriptase according to the manufacturer protocol (Q-Biogene EMMLV100, Irvine, 
USA). Fifty nanograms of cDNA combined with 1x TaqMan Universal Master Mix (Applied Biosystems, 
Foster, USA) and 1 µl of probe were loaded into each well. The Nav1.5 probe (Mm00451971), the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe (Mm99999915), the SCN1B probe 
(Mm00441210) and the Nedd4-2 probe (Mm00459584) were from Applied Biosystem. The 96 well 
thermal plate was cycled at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 
s, and 60°C for 1 min. GAPDH was used as reference gene to normalize the data. The comparative 
threshold cycle relative quantification method was used to compare the amounts of mRNA in control 
and mdx5cv mice.  Samples were measured in duplicate. 
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Patch clamp experiments 
Only rod-shaped myocytes with distinct edges were selected for patch clamp experiments. The whole-
cell configuration of the patch-clamp technique was used to record INa. Experiments were performed at 
room temperature (22-23°C). Current recordings were performed using VE-2 (Alembic Instruments) 
amplifier. Borosilicate glass pipettes (tip resistance 1-2 mΩ) were filled with a solution containing 60 
mM CsCl, 70 mM Cesium asparte, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 11 mM EGTA and 5 
mM Na2ATP (pH was adjusted to 7.2 with CsOH). Myocytes were bathed with a solution containing 10 
mM NaCl, 120 mM NMDG-Cl, 2 mM CaCl2, 1.2 mM MgCl2, 5 mM CsCl, 10 mM HEPES, and 5 mM 
Glucose (pH was adjusted to 7.4 with CsOH).  
Holding potentials were -120 mV and INa densities (pA/pF) were obtained by dividing the peak INa by 
the cell capacitance obtained using the transient capacitive current caused by a +5 mV pulse from the 
holding potential. Peak current were measured during a current voltage protocol. To quantify the 
voltage-dependence of steady-state activation and inactivation, data from individual cell were fitted 
with Boltzmann relationship, y(Vm)=1/1+exp((Vm-V1/2)/K), in which y is the normalized current or 
conductance, V1/2 is the voltage at which half of the available channels is inactivated, k is the slope 
factor, and Vm is the membrane potential. Data are represented as mean values ± SEM. Two-tailed 
Student t-test was used to compare means. Statistical significance was set at P<0.05. 
68 
MG132 rescues Nav1.5 and INa in cardiomyocytes of mdx5cv mice 
 
Results 
MG132 rescues Nav1.5 and the sodium current in mdx5cv mice 
Recently, we showed that the cardiac voltage-gated sodium channel Nav1.5 
was part of the dystrophin multiprotein complex in human and mice cardiomyocytes2.  
We observed in mdx5cv mice, in which dystrophin is not expressed, that Nav1.5 
protein content as well as the sodium current were decreased. In addition, we found 
that the sodium channel could be ubiquitylated by ubiquitin protein ligases of the 
Nedd4 family thereby regulating the density of the channel at the cell membrane11. In 
order to determine whether the ubiquitin proteasome system is implicated in the 
diminution of the sodium channel in cardiomyocytes of dystrophin-deficient mice, we 
treated control and mdx5cv mice with the proteasome inhibitor MG132. Osmotic 
minipumps were implanted subcutaneously and delivered MG132 at a dose of 10 
µg/kg/24 h for one week. We carried out Western blot experiments using 
cardiomyocyte lysates of mdx5cv and control mice treated with MG132 or 0.9% NaCl. 
The protein content of Nav1.5 in cardiomyocytes was quantified by digital density 
measurements of several Western blots such as the one represented in figure 1A. 
Similarly to our previously published results2, we observed that the total amount of 
Nav1.5 protein is decreased by ~50% in ventricular myocytes of mdx5cv mice treated 
with the saline solution, as compared to controls. The MG132 treatment increased 
the protein level of Nav1.5 in mdx5cv cardiomyocytes to a level similar to control mice 
(figure 1A and 1B). Note that the proteasome inhibitor had no effect on Nav1.5 
protein content in control mice.  
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Figure 1: Effects of MG132 treatment on Nav1.5. (A) Representative Western blot of ventricular 
myocyte lysate of control and mdx5cv mice treated with MG132 or 0.9% NaCl as indicated. Eighty µg of 
lysate were loaded in each lane. (B) Bar graph representing the amounts of total Nav1.5 protein in 
control and mdx5cv ventricular myocytes quantified by digital density measurements. The number of 
mice used for quantification is indicated in the bars. 
 
As previously observed2 the sodium current was decreased by ~30% in mdx5cv 
as compared to control. The proteasome inhibitor had a strong effect on sodium 
current of mdx5cv cardiac cells, increasing the current to a level similar to control mice 
(figure 2A and 2B). The effect of MG132 treatment on INa was restricted to an 
increase in the channel density since voltage dependence of activation and 
inactivation were not affected by the treatment (figure 2C). Finally, we performed 
Nav1.5 mRNA quantification using real time PCR. We did not observe any significant 
differences between mdx5cv and control mice, neither in the expression level of the 
Nav1.5 transcript nor in the treatment with MG132 (figure 2D). 
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Figure 2: Effects of MG132 treatment on the sodium current. (A) Normalized current density-
voltage relationship of INa in control and in mdx5cv mice treated with MG132 or 0.9% NaCl as indicated. 
The protocol is indicated in inset. (B) Bar graph representing the amounts of sodium current in control 
and mdx5cv ventricular myocytes. 4 cells were patched for each mouse and the number of mice used 
for quantification is indicated in the bars. (C) Steady state activation and inactivation curves. (D) 
Quantitative RT-PCR experiments. Bar graph representing the amounts of Nav1.5 mRNA in control 
and mdx5cv ventricular myocytes, analyzed by Taqman® as described in Material and Methods. The 
number of mice used for quantification is indicated in the bars. Results are expressed as normalized 
mean signal intensity. *P < 0.05, n.s. = not significant.  
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MG132 does not rescue dystrophin expression in muscle 
Bonuccelli and coworkers3 previously reported that systemic treatment with 10 
µg/Kg/24 h MG132 was able to rescue the expression of dystrophin in skeletal 
muscle of the “original” mdx mice strain. We performed Western blots of mdx5cv 
gastrocnemial muscle lysates in order to determine whether dystrophin is expressed 
in skeletal muscles upon treatment with MG132. The dystrophin antibody used for 
Western blot is directed against the actin binding site in the N-terminus. The mdx5cv 
mice strain has a mutation in exon 10 which leads to a premature stop codon in the 
full-length transcript14. Thus, we may assume that if a shorter dystrophin form would 
have been produced in mdx5cv muscles upon MG132 treatment, it may have been 
detected. Our results indicate that, as expected, dystrophin expression is 
undetectable in skeletal muscle of mdx5cv mice treated with 0.9% NaCl (figure 3A)14. 
However, unlike what was previously described in the “original” mdx mice, the 
MG132 treatment did not rescue the dystrophin expression in mdx5cv cardiomyocytes 
(figure 3A). Similarly, the proteasome inhibitor treatment did not rescue dystrophin 
expression in mdx5cv skeletal muscle (figure 3B). 
Figure 3: Dystrophin is not expressed in skeletal muscle or in cardiomyocytes of mdx5cv mice 
treated with MG132. Western blots of mouse ventricular myocytes (A) and Gastrocnemius muscle (B) 
lysate of control and mdx5cv mice treated with MG132 or 0.9% NaCl as indicated.  
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MG132 treatment leads to a decreased ubiquitylation of Nav1.5 in mdx5cv mice 
The proteasome is known to degrade ubiquitylated proteins, and we have 
previously shown that a fraction of Nav1.5 is ubiquitylated in cardiac tissue11. We 
performed biochemical experiments to determine whether the MG132-mediated 
increase in Nav1.5 protein content and INa may have been caused by a modification 
of the ubiquitylation state of the sodium channel protein. Ubiquitylated fraction of 
solubilized cardiomyocyte proteins were precipitated using the S5a fusion protein. 
The S5a protein is a subunit of the 26S proteasome which binds polyubiquitin 
chains15. We performed a control experiment to assess the specificity of pull down 
precipitations. HEK293 cells were transfected with the ubiquitin ligase protein Nedd4-
2 and co-transfected or not with Nav1.5. S5a pull-downs were performed on HEK293 
lysates and precipitated fractions were subsequently loaded on a gel and blotted with 
a Nav1.5 antibody (figure 4A). In S5a pull down lanes of figure 4A, it can be seen that 
the signal for Nav1.5 is only detected in HEK293 cells expressing the sodium 
channel, which validates our experimental procedure. S5a pull downs performed on 
cardiac lysates of control and mdx5cv mice treated with the saline solution reveal that 
the signal for Nav1.5 is equivalent for three controls and three mdx5cv mice. This 
indicates that the total number of ubiquitylated channels is similar in both mice strains 
(figure 4B, left panels). Treatment with MG132 leads to a dramatic decrease in the 
Nav1.5 signal in the mdx5cv lanes as compared to control mice (figure 4B, right 
panels), indicating that inhibition of the proteasome drastically decrease the 
ubiquitylation of Nav1.5 in mdx5cv mice. Ponceau stainings indicate that similar 
amounts of fusion proteins were used. 
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Figure 4: Ubiquitylation of Nav1.5 in control and mdx5cv mice. (A) Western blot of the S5a pull 
down assay performed on a lysate of HEK293 cells transfected with Nedd4.2 and co-transfected with 
Nav1.5 or not. Forty µg of lysate were loaded in each lane for the input.  (B) Western blots of pulled-
down fractions performed on mouse ventricular lysate of either control or mdx5cv mice upon MG132 or 
0.9% NaCl treatment as indicated. The Ponceau staining of the fusion proteins is shown in the bottom 
panel. 
Nedd4-2 and the β1-subunit of Nav1.5 are not affected by MG132 treatment 
Recently, we obtained evidence that Nav1.5 was regulated by the ubiquitin 
ligase protein Nedd4-211. Alternatively, it was shown that β-subunits of Nav1.5 could 
modulate the channel activity16. In addition, recent studies revealed that the β1-
subunit of Nav1.5 (encoded by the gene SCN1B) was down-regulated in skeletal 
muscle of DMD patients17.  In order to determine whether these proteins could 
regulate Nav1.5 in mdx5cv mice or upon MG132 treatment, we performed real time 
PCR experiments to quantify relatives mRNA amounts. The bar graph presented in 
figure 5A and 5B show no difference between the different tested conditions, 
suggesting that these proteins are not likely to be involved in the modulation of 
Nav1.5. 
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Figure 5: Quantitative RT-PCR experiments. Bar graph representing the amounts of Nedd4-2 (A) 
and SCN1B (B) mRNA in control and mdx5cv ventricular myocytes, analyzed by Taqman® as 
described in Material and Methods. The number of mice used for quantification is indicated in the 
bars. Results are expressed as normalized mean signal intensity. n.s. = not significant. 
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Discussion 
A recent study3 has shown that treatment of the dystrophin null mice with the 
proteasome inhibitor MG132 was able to rescue the expression of dystrophin in the 
skeletal muscle. However the authors did not investigate the effect of MG132 on the 
cardiac muscle. In the mdx5cv mouse strain, we previously2 showed that Nav1.5 
protein content was specifically decreased by ~50% and that the sodium current was 
also decreased by ~30%. Heterologous expression system studies have shown that 
Nav1.5 could be ubiquitylated and that this ubiquitylation led to decreased INa. In the 
present work, we treated control and mdx5cv mice with MG132 to investigate the 
implications of the ubiquitin proteasome system on the regulation of  Nav1.5. The 
main findings of this study are: (1) proteasome inhibitor MG132 rescues the sodium 
channel Nav1.5 and the sodium current in mdx5cv cardiomyocytes; (2) MG132 does 
not rescue the dystrophin expression in cardiac or skeletal muscle; and (3) MG132 
treatment leads to a decrease in the level of Nav1.5 ubiquitylation.  
MG132 rescues Nav1.5 and the sodium current in mdx5cv mice 
The proteasome is a proteolytic complex which rapidly degrades ubiquitylated 
proteins. MG132 is a molecule which reversibly blocks protein degradation by the 
proteasome18. In this study we show that treatment of mdx5cv mice with the 
proteasome inhibitor MG132 rescues the total amount of Nav1.5 protein and the 
sodium current (figure 1 and 2B) in cardiomyocytes. These results suggest that the 
decrease of Nav1.5 observed in mdx5cv mice could be either directly or indirectly 
mediated by the proteasome. However, it is more likely that the proteasome is 
indirectly implicated in the regulation of Nav1.5. Indeed, in eukaryotic cells, 
membrane associated proteins are primarily degraded by the lysosomal apparatus 
whereas the proteasome is involved in the proteolysis of cytosolic proteins19. In 
addition, the proteasome is also probably implicated in the regulation of endocytic 
transport 20. It is known that the activity of endocytic proteins is regulated by ubiquitin 
signals and the proteasome could control the degradation of these ubiquitylated 
proteins20. However, components of the endocytic machinery that undergo 
ubiquitylation are primarily monoubiquitylated and proteasome recognises 
polyubiquitylated proteins. It was therefore suggested that endocytic proteins could 
be transiently polyubiquitylated and degraded by the proteasome 21. However 
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endocytic proteins which could be degraded by the proteasome have not been 
identified so far. Altogether, these results suggest that the proteasome can indirectly 
regulate Nav1.5. Therefore, additional experiments using endocytosis or lysosome 
inhibitors should be carried out in order to identify the proteolytic pathway involved in 
the degradation of Nav1.5. 
MG132 does not rescue dystrophin expression in muscle 
It is important to consider that unlike Bonuccelli and coworkers3, we did not use 
the “original” mdx mice strain which carries a premature stop codon in exon 23, since 
this strain was shown to have revertant fibers due to exon skipping events22. In the 
present study we used the mdx5cv mice strain which carries an A to T mutation in the 
middle of exon 10 that produces a new splice donor site and generates a premature 
stop codon in the full-length transcripts14. In the present study, MG132 treatment of 
mdx5cv mice does not rescue dystrophin expression in skeletal and cardiac muscle. 
The different effects of MG132 treatment on the two mouse strains could be due to 
the nature of dystrophin mutations. The mutation on the dystrophin gene of mdx5cv 
mice may produce an unstable transcript which may not be translated whereas the 
“original” mdx strain may produce an unstable protein that could accumulate upon 
MG132 treatment. This interpretation is supported by the study performed by 
Assereto and coworkers23 on the dystrophin multiprotein complex composition of 
DMD and BMD muscle explants following in vitro treatment  with 20 µM MG132. The 
authors showed that only some of the DMD and BMD explants showed signs of DMC 
rescue (after MG132 treatment) probably due to the nature of dystrophin mutations. 
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Ubiquitylation of Nav1.5 is decreased upon treatment with MG132 
Using the S5a subunit of the proteasome as GST fusion protein, we were able 
to precipitate a polyubiquitylated fraction of cardiomyocyte lysates. Using this 
approach we found that the amount of ubiquitylated sodium channel was similar 
between untreated mdx5cv and control mice whereas the total amount of Nav1.5 
protein in mdx5cv was half the amount of control mice (Figure 1). Several explanations 
can be formulated to describe this phenomenon. There is no experimental evidence 
of the role of monoubiquitylation versus polyubiquitylation of the sodium channel. 
Therefore, we do not known if polyubiquitylation of Nav1.5 is a signal for endocytosis 
and degradation or a signal for another cellular process (i.e. polyubiquitylation is a 
signal for the degradation of misfolded proteins during the protein biosynthesis). If we 
assume that polyubiquitylation could be a signal for degradation we could 
hypothesize that ubiquitylated Nav1.5 undergo rapid degradation and do not 
accumulate in the cell. In this context it would be very important to perform additional 
experiments to quantify the fraction of monoubiquitylated and polyubiquitylated 
sodium channel. 
We observed that MG132 treatment induced a decrease in the ubiquitylation 
level of Nav1.5 in mdx5cv mice (figure 4B) associated with a rescue of Nav1.5 protein 
and INa (figure 1 and 2B). It has already been reported that proteasome inhibition 
could lead to free ubiquitin depletion in cells24. Indeed, the proteasome has an 
ubiquitin recycling activity which maintains constant the level of free ubiquitin in the 
cell. Thus, upon proteasome blockade, the level of free ubiquitin in the cytoplasm 
falls down. This phenomenon could lead to an important reduction of the endocytosis 
and lysosomal activity and thus lead to an increase of Nav1.5 at the plasma 
membrane. Therefore additional experiments quantifying the amount of free ubiquitin 
in the cells upon MG132 treatment should be performed to address this issue. 
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Conclusion 
Our previous study2 suggested that dystrophin deficiency could lead to the 
destabilization of Nav1.5 at the plasma membrane. The present work suggests that 
the proteasome is directly or indirectly implicated in the decrease of Nav1.5 protein 
and INa observed in mdx5cv. Treatment of mdx5cv mice with proteasome inhibitor 
MG132 rescued the total amount of Nav1.5 protein and the sodium current of mdx5cv 
cardiomyocytes but not the dystrophin expression. Our results also indicate that 
proteasome inhibition is associated with a decrease in the amount of 
polyubiquitylated Nav1.5 in mdx5cv animals which could be secondary to ubiquitin 
depletion of cells. 
Based on our experimental results, we cannot conclude whether the 
proteasome directly degrades polyubiquitylated Nav1.5 or if it regulates the endocytic 
machinery which controls the amount of sodium channel at the plasma membrane. In 
this context it would be very important to perform additional experiments (e.g. using 
lysosomal protease inhibitors) to understand the degradation of Nav1.5 in dystrophin 
deficient animals.  
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 IV.3 Publication 3 
Aldosterone increases voltage-gated sodium current 
in ventricular myocytes. 
Boixel C*, Gavillet B*, Rougier JS, Abriel H.  
American journal of physiology. Heart and circulatory physiology 2006 Jun; 
290(6):H2257-66. Epub 2006 Jan 20. 
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This study aimed at elucidating the effects of aldosterone on cardiac sodium 
current. For this purpose, isolated mouse ventricular myocytes were treated 24 h with 
high doses of aldosterone ranging from 10 nM to 1 µM. Electrophysiological 
measurements have shown that aldosterone treatment was increasing the sodium 
current by 55% with no alteration of the channel biophysical parameters.  
Aldosterone was also shown to significantly prolong the action potential duration. The 
effect of aldosterone on the sodium current was blocked by the mineralocorticoid 
receptor (MR) antagonist spironolactone but not with the glucocorticoid receptor (GR) 
antagonist RU-38486, suggesting the implication of MR in the aldosterone response.  
However, due to the lack of specificity of MR and GR agonists and inhibitors (e.g. 
spironolactone also binds to GR) we were not able to exclude the implication of the 
GR. Quantitative RT-PCR and Western blots did not show any significant 
modification of the mRNA or protein level of Nav1.5. Altogether these results indicate 
that high doses of aldosterone can alter the electrical properties of cardiac myocytes. 
Additionally, this study is the first to report effects of aldosterone on cardiac sodium 
currents. However, additional experiments should be performed in genetically 
modified animals to assess the specificity of aldosterone effects on MR vs. GR. 
 
 
Contribution to the paper: 
In this paper I performed all the biochemical experiments and all quantitative 
RT-PCR experiments. I also isolated and treated mouse ventricular myocytes used 
for patch-clamp experiments. 
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The role of aldosterone in the pathogenesis of heart failure (HF) is still
poorly understood. Recently, aldosterone has been shown to modulate
the function of cardiac Ca2 and K channels, thus playing a role in
the electrical remodeling process. The goal of this work was to
investigate the role of aldosterone on the cardiac Na current (INa).
We analyzed the effects of aldosterone on INa in isolated adult mouse
ventricular myocytes, using the whole cell patch-clamp technique.
After 24 h incubation with 1 M aldosterone, the INa density was
significantly increased (55%), without alteration of the biophysical
properties and the cell membrane capacitance. Aldosterone (10 nM)
increased the INa by 23%. In 24-h coincubation experiments, with the
use of actinomycin D, cycloheximide, or brefeldin A, the effect of
aldosterone on INa was abolished. Spironolactone (mineralocorticoid
receptor antagonist, 10 M) prevented the 1 M aldosterone-depen-
dent INa increase, whereas RU-38486 (glucocorticoid receptor antag-
onist, 10 M) did not. The action potential duration (APD) was longer
in aldosterone-treated (APD90: 53%) than in control myocytes. In
addition, the L-type Ca2 current was also upregulated (48%). We
performed quantitative RT-PCR measurements and Western blots to
quantify the mRNA and protein levels of Nav1.5 and Cav1.2 (main
channels mediating cardiac INa and ICa), but no significant difference
was found. In conclusion, this study shows that aldosterone upregu-
lates the cardiac INa and suggest that this phenomenon may contribute
to the HF-induced electrical remodeling process that may be reversed
by spironolactone.
sodium channels; calcium channels; electrophysiology; spironolac-
tone
THE MOST WELL-DESCRIBED EFFECT of the mineralocorticoid hor-
mone aldosterone is to promote transepithelial Na and K
transport in the kidney, thereby regulating blood volume and
pressure (25). However, aldosterone targets other organs, in-
cluding the heart (13). Supporting the concept that aldosterone
plays an important role in heart failure (HF), recent clinical
trials reported a significant benefit when administering miner-
alocorticoid receptor (MR) antagonists, such as spironolactone
or eplerenone to HF patients, thus reducing the overall mor-
bidity and mortality (33, 34). In the Eplerenone Postacute
myocardial infarction Heart failure Efficacy and Survival
Study (EPHESUS) study (33), eplerenone reduced by 21% the
occurrence of sudden cardiac death (SCD), a major cause of
death in HF patients (8). Hence, it may be hypothesized that
HF-induced hyperaldosteronemia has direct or indirect pro-
arrhythmogenic properties. Among several possible patholog-
ical mechanisms, it has been proposed that aldosterone plays a
major role in the evolution of chronic HF by promoting
structural remodeling in the cardiac tissue (46). More recently,
studies (2, 3, 22, 28, 30–32) have reported that aldosterone
might also modulate the cardiac function by altering ion
transporters in cardiac myocytes and may consequently under-
lie the electrical disorders observed in HF patients. For exam-
ple, aldosterone has been shown to increase the L-type Ca2
current (ICa) and decrease transient outward current (Ito) in rat
ventricular cardiomyocytes (2, 3). Moreover, investigating
mice models with hypo- and hyperaldosteronemia, Perrier et al.
(32) recently demonstrated that ICa was also upregulated in
vivo. In neonatal rat cardiomyocytes, the gene expression of
the 1- and 1-subunits of the Na-K-ATPase was shown to
be stimulated by aldosterone (19). Furthermore, aldosterone
stimulates the T-type Ca2 current by promoting channel
expression in human adrenocarcinoma cells (23). However,
currently nothing is known about a possible effect of aldoste-
rone on the Na current (INa) and Na channels in cardiac
myocytes, despite the fact that these channels have been shown
to play a major role in different types of genetically determined
arrhythmias causing SCD (37).
The main cardiac voltage-gated Na channel Nav1.5 plays a
pivotal role in the excitability and conduction of electrical
impulses in the heart. Although the structure, function, and
pharmacology of Nav1.5 have been studied in detail, the
regulation of its gene expression and trafficking remains poorly
understood (18). In recent reports (14, 35, 41), the cell surface
density of Nav1.5 channels has been shown to be regulated by
the activity of Nedd4–2, an E3 ubiquitin-protein ligase. The
current working model proposes that Nav1.5 may be ubiquiti-
nated by ubiquitin ligases and that such ubiquitinated channels
are recognized by the cellular internalization machinery (35),
thus determining the channel density at the cell surface. In
kidney distal tubular cells, aldosterone has been shown to
indirectly regulate Nedd4–2 activity via stimulation of the
expression of the protein kinase Sgk1 that can phosphory-
late and inactivate Nedd4–2 by thus far unknown mecha-
nisms (10).
Based on these clinical and molecular findings, the main aim
of this work was to investigate whether the cardiac INa would
also be regulated by pathological concentrations of aldoste-
rone, i.e., ranging from 10 nM to 1 M. In this study, we report
that 24 h treatment of isolated mouse ventricular myocytes
with aldosterone increased the INa density without affecting its
biophysical properties. The effect of aldosterone on INa was
totally blocked by inhibitors of transcription, protein synthesis,
and trafficking, as well as with spironolactone. A similar
increase of INa was obtained with the glucocorticoid dexameth-
asone. However, we observed no effect on the mRNA levels of
Nav1.5, the total cellular Nav1.5 protein pool, and on Nedd4–2
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expression and phosphorylation. These results suggest that
pathological concentrations of aldosterone increase the density
of cardiac Na channels at the cell surface via the activation of
so far unknown genes involved in the regulation of its traffick-
ing and/or membrane stability.
MATERIALS AND METHODS
Cardiomyocytes isolation. Adult mouse ventricular myocytes were
isolated from male C57BL/6 mice (25–30 g, Janvier, France). Ani-
mals were anesthetized with pentobarbital and, after heparinization,
the chest was opened; hearts were excised and subjected to retrograde
perfusion (3 ml/min) in a Langendorff apparatus with a solution
containing (in mmol/l): 4.75 KCl, 1.2 KH2PO4, 35 NaCl, 16
Na2HPO4, 25 NaHCO3, 10 HEPES, 10 glucose, and 134 sucrose; pH
7.4 at 37°C for 3 min. During isolation, 2,3-butanedione oxime (10
mmol/l) was added to the solution to prevent cell damage during the
perfusion. Hearts were then perfused with the same solution contain-
ing type II collagenase (Worthington Biochemical) for approximately
15 min. Ventricular myocytes were then isolated by several low-speed
centrifugations (7 g, 1 min). Myocytes were resuspended in Dulbec-
co’s modified Eagle’s medium (DMEM), supplemented with 10%
fetal calf serum (GIBCO), 4% nonessential amino acids (GIBCO),
insulin-selenium-transferrin (GIBCO), 100 IU/ml penicillin, and 0.1
mg/ml streptomycin (GIBCO). Cytosine -D-arabino-furanoside (10
mol/l, Sigma) was added to the medium to inhibit the proliferation
of nonmuscle cells. Myocytes were then plated on laminin-coated
dishes (Sigma). After an adhesion period of 1 h, myocytes were rinsed
twice with serum-free culture medium to eliminate nonadherent cells,
dead cells, and debris. The 24-h treatments were conducted in serum-
free medium. Animal experiments were performed in accordance with
Swiss law. They were submitted and approved by the Veterinary
Office of Canton Vaud.
Patch-clamp measurements. The whole cell configuration of the
patch-clamp technique was used to record INa and action potentials
(AP). Experiments were performed at room temperature (22–24°C).
Current and AP recordings were performed using VE-2 (Alembic
Instruments) and Multiclamp 700A (Axon Instruments) amplifiers,
respectively. For INa, glass pipettes ( resistance: 1–2 M) were filled
with a solution containing (in mmol/l) 60 CsCl, 50 aspartic acid, 1
CaCl2, 1 MgCl2, 10 HEPES, 11 EGTA, and 5 Na2ATP (pH 7.3 with
CsOH). For APs, the internal solution was (mmol/l): 10 NaCl, 130
KCl, 2 CaCl2, 10 glucose, 1 MgCl2, 10 HEPES, 3 Na2ATP, and 5
EGTA (pH 7.3 with KOH). Myocytes were bathed with a solution
containing (in mmol/l) 137 NaCl, 5 KCl, 2 CaCl2, 10 glucose, 1
MgCl2, and 10 HEPES (pH 7.4 with NaOH). For current recordings,
external Na was reduced to 14 mM using N-methyl-glucamine as a
Na substitute, and KCl was replaced by an equal amount of CsCl.
The values were not corrected for the measured 16-mV junction
potential. The amplitude of INa monitored according to a steady-state
pulse protocol (a 20-ms depolarizing pulse to20 mV from a holding
potential of 80 mV) was calculated as the difference between the
peak inward current and the current measured at the end of the test
pulse, and its density (pA/pF) was obtained by dividing INa amplitude
by the membrane capacitance. Cell capacitance was calculated by
using the transient capacitive current caused by a 5-mV pulse from
the holding potential. To quantify the voltage dependence of steady-
state activation and inactivation, data from individual cells were fitted
with the Boltzmann relationship, y  (Vm)  1/1  exp[(Vm  V1⁄2)/K],
in which y is the normalized current or conductance, V1⁄2 is the voltage
at which half of the available channels are inactivated, K is the slope
factor, and Vm is the membrane potential. The voltage dependence of
inactivation was determined by measuring current in response to
pulses (20 ms) to 20 mV that had been preceded by 500-ms pulses
applied in a series of 5-mV incremental voltages. All experiments
were started after an equilibration period until peak INa was stable.
APs were elicited by 40-pA depolarizing current pulses. These stimuli
were delivered for a 4-ms test pulse at 0.5 Hz, and the resting
potential, the amplitude of the AP, and the AP durations (APDs) from
the peak of the AP to the 30, 50, and 90% repolarization level (APD30,
APD50, and APD90) were measured. Average of APs (30 per myo-
cyte) recorded from aldosterone-treated myocytes was compared with
that of control myocytes.
Western blot experiments. Cultured cardiomyocytes were rinsed
twice with phosphate-buffered solution, and lysis buffer was added
[20 mM Tris, pH 7.5, 100 mM NaCl, 1% Triton X-100, 1 mM PMSF,
and complete protease inhibitor cocktail (Roche)]. Lysates were
rotated for 60 min at 4°C to allow solubilization of proteins. The
soluble fraction of a 10-min centrifugation at 13,000 g was recovered
and used for Western blot experiments after dilution in 1 SDS
sample buffer. The reagents used were 30% acrylamide/bis-
acrylamide (37.5:1 vol/vol) solution from National Diagnostics.
N,N,N	,N	-Tetramethylethylenediamine, ammonium persulfate, and
PMSF were from Acros (Belgium). Nitrocellulose sheets (0.2 m
pore size) were from Schleicher & Schuell. BSA and Bradford reagent
solution were purchased from Uptima (France). Horseradish peroxi-
dase-conjugated anti-rabbit secondary antibody and protein-A-Sepha-
rose are from Amersham. Western blots were developed using Super-
Signal West-Dura Extended Duration Substrate (Pierce). ECL signals
were recorded on Kodak X-OMAT AR film. For the protein gels,
1.5-mm-thick minigels (Bio-Rad system) were cast using a 5–15%
acrylamide gradient. Typical runs were carried out at 200 V for 55
min. Proteins were transferred to nitrocellulose using a submarine
system: transfer buffer consisted of 18.6 mM Tris, 140 mM glycine,
20% methanol, and 0.1% SDS. Typical transfers were carried out at
100 V for 200 min keeping the transfer apparatus in an ice bath.
Membranes were blocked for at least 60 min in blocking solution [5%
skim milk solution in Tris-buffered saline 0.1% Tween (TBS-
Tween)]. Antibodies and sera were prepared in a 5% BSA solution in
TBS-Tween. After 3 5-min washes in TBS-Tween, membranes
were incubated again with blocking solution for 15 min after which
secondary antibody was added. After a 1-h incubation at room
temperature under agitation, membranes were washed as above and
bound immunoglobulins were revealed by ECL.
TaqMan real-time quantitative PCR. RNA was extracted from 2 
105 myocytes cultured for 24 h using Quiagen RNeasy (Quiagen,
Germany). cDNA was synthesized from 500 ng of total RNA using
the MU-MLV reverse transcriptase according to the manufacturer
protocol (Q-Biogene EMMLV100). Thirty nanograms of cDNA com-
bined with 1 TaqMan Universal Master Mix (Applied Biosystems)
and 1 l of either Nav1.5, Cav1.2 or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe (Applied Biosystems respectively
Mm99999915, Mm00437917 and Mm00451971) were loaded into
each well. The 96-well thermal plate was cycled at 50°C for 2 min and
95°C for 10 min, followed by 40 cycles at 95°C for 15 s, and 60°C for
1 min. Data were collected and analyzed using the threshold cycle (Ct)
relative quantification method (24). The GAPDH reference gene was
used for data normalization.
Antibodies and reagents. Anti-Nav1.5 rabbit serum (ASC-005,
Alomone) and a monoclonal anti-actin (A2066, Sigma Chemical)
antibody were used. Anti-Nedd4–1, anti-Nedd4–2, and anti-phospho-
Nedd4–2 antibodies have been described elsewhere (15, 20). A
specific Cav1.2 (1C) antibody was kindly provided by Dr. J. Hell
(University of Iowa). The anti-Sgk1 antibody was purchased at
Upstate (07-315). The polyclonal antibody raised against the terminal
14 residues of 1 was kindly provided by Dr. L. Isom (University of
Michigan). Actinomycin D, D-aldosterone, and dexamethasone were
dissolved in DMSO (100%), and brefeldin A, cycloheximide,
RU38486, and spironolactone were prepared in ethanol (100%) until
used. The final concentration of DMSO and ethanol alone had no
effect on INa (data not shown). All drugs were from Sigma (Buchs,
Switzerland).
Statistical analyses. Values are expressed as means 
 SE. Mann-
Whitney test was used when comparing two groups, and Kruskal-
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Wallis procedure followed by a Dunn’s posttest was used to compare
more than two groups. Statistical significance is set at P  0.05.
RESULTS
Aldosterone prolongs the AP duration and upregulates ICa
in mouse ventricular myocytes. In the present study, we per-
formed short-term (up to 24 h) primary cultures of adult mouse
ventricular myocytes that were exposed to high concentrations
of aldosterone for different time intervals. First, we carried out
a set of experiments aimed at validating this cellular model.
The functional consequences of the aldosterone treatment were
studied by analyzing the shape of the AP in isolated mouse
ventricular myocytes treated or not treated with aldosterone.
Figure 1A shows representative traces of AP from mouse
ventricular myocytes treated for 24 h with 1 M aldosterone
and control conditions, recorded under current-clamp condi-
tions. Whereas the resting membrane potential was unchanged
(control: 73.7 
 1.1 mV, aldosterone: 73.3 
 1.2 mV, Fig.
1B), the mean peak AP value (Fig. 1C) tended to be higher in
aldosterone conditions (44.4 
 2.6 mV) than in control
myocytes (41.3 
 2.6 mV), but this result did not reach
statistical significance. As illustrated in Fig. 1D, repolarization
of 90% of the APD was significantly prolonged in myocytes
incubated with aldosterone (48.7 
 3.0 ms) compared with
control conditions (31.9 
 1.2 ms). We then tested whether in
mouse ventricular myocytes the L-type Ca2 current (ICa) is
modulated similarly to what has been reported in rat myocytes
(3). Because variations in cell size might account for differ-
ences in current amplitudes, we have normalized the measured
currents to the membrane capacitance, which was on average
124.1 
 4.0 pF in control (n  22) and 132.7 
 5.8 pF (n 
22) in aldosterone conditions (not significantly different). Fig-
ure 2A shows that ICa density was increased in mouse myocytes
treated with 1 M aldosterone for 24 h (48%) compared with
control conditions, with no apparent shift in the current-voltage
relationship (Fig. 2B). To investigate the mechanisms under-
lying this current increase, the mRNA levels of the Cav1.2 gene
(CACNA1C) from myocytes cultured under the two conditions
were quantified using specific TaqMan probes (see MATERIALS
AND METHODS), but no difference was observed (Fig. 2C).
Furthermore, Fig. 2D shows a representative Western blot
performed using an anti-Cav1.2 antibody (17), illustrating that
despite the upregulated ICa density, aldosterone did not in-
crease the total amount of cellular Cav1.2 protein. Note that to
test whether a 1.5-fold increase may have been observed under
our experimental conditions, we loaded increasing amounts of
myocyte lysate (1-1.5–2) in one gel, and it is apparent
that such a difference could have been detected (Fig. 2E).
These data indicate that aldosterone may significantly alter
the electrical activity of mouse cardiac cells and confirm recent
findings obtained by Be´nitah et al. (2, 3) studying the effect of
aldosterone on rat cardiomyocytes, using similar protocols.
Moreover, these results validate our experimental conditions.
Aldosterone upregulates INa in mouse ventricular myocytes.
After this first set of experiments, we focused on the modula-
tion of the cardiac INa by high concentrations of aldosterone,
Fig. 1. Aldosterone (Aldo) increases the action potential
(AP) duration (APD) in mouse ventricular myocytes. A:
superimposition of APs recorded from cardiac cells in
absence (E) or presence (F) of 1 M Aldo for 24 h. B–C:
resting membrane potential and peak of AP in control
(open bars) and Aldo (solid bars) conditions. NS, not
significant. D: APD at 30, 50, and 90% repolarization of
isolated myocytes in control (open bars) and Aldo (solid
bars) conditions. ***P  0.001, Mann-Whitney; B–D:
n  13–14 cells.
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which was the main goal of our study. Figure 3 shows repre-
sentative examples of voltage-gated inward Na currents re-
corded in myocytes treated with (Fig. 3B) or without (Fig. 3A)
1 M aldosterone for 24 h. As shown in Fig. 3D, the peak INa
density was significantly higher in aldosterone-treated myo-
cytes (55%) compared with control conditions. After 24 h
incubation with the MR synthetic agonist fludrocortisone (1
M), the INa density was increased by96% (Fig. 3, C and D).
We also treated myocytes with lower concentrations of aldo-
sterone that are in the range of the measured intracardiac
concentrations (16 nM) (11) . As shown on the current-voltage
curves (Fig. 3E), 10 and 100 nM significantly increased the INa
peak current by 23% and 35%, respectively. Analysis of the
voltage dependence of INa activation and inactivation proper-
ties at steady state in control and 1 M aldosterone-treated
conditions revealed no difference between the parameters stud-
ied (Fig. 4). To study a possible rapid effect of aldosterone, we
perfused isolated myocytes that were cultured under control
conditions for 4 or 24 h, with 1 M aldosterone. However, no
modification of INa was seen under each condition (data not
shown). We also tested whether adding 1 M aldosterone into
the patch pipette solution would regulate INa. One minute after
the rupture of the membrane patch, the control and aldosterone
currents were 153 
 22 pA/pF (n  5 cells) and 142 
 21
pA/pF (n  6), respectively, whereas the INa density values
after 9 min were 150 
 20 pA/pF for control currents and
144 
 17 pA/pF for aldosterone currents. The values at 9 min
are not significantly different compared with the 1-min values
in both conditions. Finally, in myocytes cultured with 1 M
aldosterone for 4 h, no change in INa was observed. These
results suggest that a rapid nongenomic effect of aldosterone
(26) is not responsible for the increased INa.
Pharmacological evidence for MR involvement in aldoste-
rone-dependent upregulation of INa. Most biological actions of
aldosterone are mediated by its binding to intracellular miner-
alocorticoid DNA-binding receptors, which, once activated,
Fig. 2. Upregulation of L-type Ca2 current (ICa) by
Aldo. A: representative ICa traces (protocol in inset)
obtained from ventricular myocytes in control and after
1 M Aldo treatment for 24 h. B: current density-
voltage relationships of ICa in myocytes after control
and Aldo treatment, *P  0.05, Mann-Whitney. C:
quantitative PCR experiments. Bar graph representing
amount of Cav1.2 mRNA in control myocytes or treated
for 24 h with 1 M Aldo. Number of mice is indicated
in the bars. For each animal, analysis was performed in
duplicate; results were obtained as cycle threshold (Ct)
and normalized to the reference gene GAPDH. D:
representative Western blots showing the levels of
expression of Cav1.2 under control and Aldo condi-
tions. Specificity of Cav1.2 antibody was tested using
transfected HEK-293 cells. Forty micrograms of pro-
tein were loaded for the HEK-293 lysates, and 80 g of
protein were loaded for myocytes lysates. Four of such
experiments yielded comparable results. Protein load-
ing was controlled by anti-actin immunoblotting. E:
control anti-Cav1.2 Western blot performed with in-
creasing amounts of total protein (40, 60, and 80 g/
lanes).
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modulate gene expression (16). To study the role of MR in
aldosterone-induced increase in INa, we investigated the effect
of spironolactone (MR antagonist, SP) added to the culture
medium. The aldosterone-induced increase in INa was pre-
vented by SP (10 M), as shown in Fig. 5A.
Because aldosterone may also bind to the glucocorticoid
receptors (GR) (12), we investigated the action of aldosterone
in myocytes co-incubated with RU-38486, a GR antagonist (6).
However, to determine an appropriate GR-inhibitory concen-
tration of RU-38486, myocytes were first treated for 24 h with
1 M dexamethasone in presence or not of 10 M RU-38486.
At this concentration, dexamethasone is expected to fully
activate GRs (9). As shown in Fig. 5B, dexamethasone signif-
icantly increased the peak INa density (102%) compared with
control conditions. This effect was abolished by co-incubation
of RU-38486. However, Fig. 5C shows that 10 M RU-38486
did not block the aldosterone-dependent upregulation of INa.
We also tested the effect of aldosterone (1 M, 24 h) incuba-
tion on HEK-293 cells stably expressing Nav1.5, but under
these conditions the INa density was not modified (Fig. 5D).
Cellular mechanisms responsible for the aldosterone-in-
duced increase in INa. Classical aldosterone effects are medi-
ated by the interaction of intracellular MR proteins with pro-
moters of target genes, thus enhancing their transcription (16).
Hence, aldosterone modulation of cardiac INa may be due to an
increase in channel density at the cell surface through stimu-
lation of mRNA transcription and consequent protein expres-
sion. To elucidate the cellular mechanisms of aldosterone on
INa, myocytes were incubated with aldosterone for 24 h in the
presence of actinomycin D (inhibitor of transcription, 1 g/
ml), cycloheximide (protein synthesis inhibitor, 10 g/ml), or
brefeldin A [BFA, inhibitor of the protein traffic in the secre-
tory pathway (21), 10 g/ml]. As illustrated in Fig. 6A,
actinomycin D, cycloheximide, or BFA prevented the increase
in INa induced by aldosterone. Under control conditions, treat-
ment with each compound alone had no significant effect on
INa (Fig. 6B). Altogether, these results suggest that the aldo-
sterone-induced INa increase is dependent on either stimulation
of Nav1.5 expression and/or other genes involved in trafficking
of Nav1.5.
Fig. 3. Aldo stimulates Na current (INa) in ventricular myo-
cytes. A–C: representative traces of INa recorded (protocol in
inset) in ventricular myocytes after 24 h of incubation in control
(A), 1 M Aldo (B), and 1 M fludrocortisone (C). D: current
densities in control, Aldo, and fludrocortisone conditions. **P
0.01 and ***P  0.001, Mann-Whitney. When the holding
potential was 120 mV, Aldo increased the INa peak current by
50% (not shown, n  14–15 cells). E: normalized current
density-voltage relationships of INa in control and with increas-
ing Aldo concentrations. *P  0.05 compared with control.
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To address the question of whether the aldosterone-depen-
dent stimulation of INa is due to an increased Nav1.5 expres-
sion, we first performed RT-PCR quantification of the SCN5A
gene by using RNA samples extracted from myocytes treated
with either aldosterone or dexamethasone for 24 h (both 1
M). As shown in Fig. 6C, the Nav1.5 mRNA levels were not
modified upon these incubations compared with control con-
ditions. Afterwards, we performed Western blot analysis of the
proteins isolated from the myocytes, and Fig. 6D shows that
both treatments did not modify the total cellular pool of Nav1.5
expressed in cardiac cells. Note that Fig. 6E indicates that a
1.5-fold increase in Nav1.5 total cellular expression should not
have been missed under our conditions. These results suggest
that the observed steroid-dependent INa increase is not due to a
stimulation of the genomic expression of Nav1.5 but rather to
other factors.
Recently, we and others (14, 41) obtained evidence that the
Nav1.5 cell membrane density is regulated by the activity of
the protein-ubiquitin ligase Nedd4–2. We therefore measured
by Western blot analysis the protein levels of Nedd4–2 and
phosphorylated (inactive) Nedd4–2 (15) under aldosterone,
dexamethasone, and control conditions. The representative
Western blots presented in Fig. 6D show no difference between
the different tested conditions, again suggesting that other gene
products are mediating the aldosterone effect on INa. We also
tested the expression of Nedd4–1, which is another member of
the Nedd4-like family of genes binding to Nav1.5 (14, 35);
Sgk1, a kinase that can phosphorylate Nedd4–2 (10), and the
1-subunit of the Nav1.5 channel. The expression of all tested
proteins was not influenced by either aldosterone or dexameth-
asone (Fig. 6D).
DISCUSSION
About 50% of HF patients die of SCD because of ventricular
arrhythmias (8). Two recent large clinical trials (33, 34) pro-
vided evidence that MR antagonists, including spironolactone,
reduce the mortality due to SCD, supporting the hypothesis
that HF-induced hyperaldosteronemia may be proarrhythmo-
genic. However, thus far the influence of increased levels of
aldosterone on cardiac ion channels, which are key molecular
players in the genesis of arrhythmias, is still poorly understood.
The main novel finding of this study is that aldosterone also
upregulates the INa recorded in mouse ventricular myocytes,
similarly to what has been previously shown for ICa (3). The
aldosterone-dependent INa increase was abolished by co-incu-
bation with spironolactone, actinomycin D, cycloheximide, or
brefeldin A but not with the GR antagonist RU-38486. Inter-
estingly, the levels of expression of Nav1.5 and Cav1.2 mRNAs
and proteins were not increased by the steroid hormone treat-
ments.Fig. 4. Steady-state activation and inactivation properties after Aldo treatment.
Activation properties were determined from current-voltage (I-V) relationships
by normalizing peak INa to driving force and maximal INa and plotting
normalized conductance vs. membrane potential (Vm). Protocols used are in
insets. Boltzmann curves of individual cells were fitted to steady-state activa-
tion data: control V1⁄2 35.3
 1.6 mV, K 6.2
 0.5; Aldo V1⁄2 35.9

1.6 mV; K  5.9 
 0.3, where V1⁄2 is the voltage at which half of the available
channels are inactivated; and K is the slope factor. Voltage dependence of
steady-state inactivation parameters were the following: control V1⁄2 
75.5 
 0.7 mV, K  6.5 
 0.1, Aldo V1⁄2  76.0 
 0.7 mV; K  7.0 

0.3. Differences between groups were not statistically significant (Mann-
Whitney).
Fig. 5. Stimulatory effect of Aldo is mediated by mineralocorticoid receptors.
A: comparison of INa densities among control, 24 h 1 M Aldo, and 1 M
Aldo  10 M spironolactone (SP). **P  0.01, Dunn’s posttest. B: current
densities of INa in control, 1 M dexamethasone (DEX), and DEX  10 M
RU-38486 (glucocorticoid receptor antagonist) conditions. *P  0.05, Dunn’s
posttest. C: current densities of INa recorded from myocytes under control
conditions and treated with 1 M Aldo or 1 M Aldo  10 M RU-38486.
*P  0.05, Dunn’s posttest. D: current densities of INa recorded from
HEK-293 cells stably expressing Nav1.5 under control conditions and treated
with 1 M Aldo.
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Mineralocorticoid and glucocorticoid hormones regulate
cardiac ion channels. In previous works, Be´nitah and cowork-
ers reported that cardiac ion channels can be regulated by
aldosterone (2, 3). Using experimental protocols similar to the
present study, they showed that aldosterone stimulates ICa in
rat ventricular myocytes and that Ito was downregulated, both
effects leading to a prolongation of the APD (2, 3). In this
study, we confirm the effect of aldosterone on APD and ICa,
using mouse ventricular myocytes (Figs. 1 and 2) but, inter-
estingly, we also show that INa is upregulated. Further support-
ing a role for aldosterone in electrical remodeling processes in
heart diseases, a recent study in rat showed that ICa and L-type
Ca2 channel mRNAs are upregulated 1 wk postinfarction of
the left ventricle and that this effect was prevented by using the
MR antagonist RU-28318 (30). However, the regulation of INa
was not investigated in this work. Aldosterone-dependent reg-
ulation of ICa (2, 3) and INa (this study) in ventricular myocytes
displays many similarities, suggesting that the mechanisms
underlying these effects may be overlapping. However, thus far
no study addressed this possibility.
In the studies mentioned above, the role of MRs in mediat-
ing the effects of aldosterone, i.e., modulation of cardiac
currents, is suggested by the fact that the MR antagonist
spironolactone blocks its action. However, these findings may
also in part reflect the antiglucocorticoid effect of spironolac-
tone when partially binding to GRs, which has been shown to
occur with an apparent Kd of 2 M (9). Moreover, it should be
pointed out that the functional role of MRs and their protection
from cortisol occupancy by the activity of the 11--hydroxy-
steroid-dehydrogenase type 2 in cardiac myocytes is still a
matter of controversy (13) and, as a result, the specific roles of
MRs and/or GRs in these regulatory pathways remain to be
clarified. Because the pharmacological approaches used in the
mentioned studies (2, 3), as well as our present work, may be
Fig. 6. Cellular mechanisms of Aldo -mediated INa
stimulation. A: INa densities recorded from myo-
cytes in control or treated with 1 M Aldo alone or
with actinomycin D, cycloheximide, or brefeldin A.
**P  0.01, Dunn’s posttest. B: normalized INa
recorded from myocytes in control or treated with
actinomycin D, cycloheximide, or brefeldin A
alone; groups were statistically not different
(Kruskal-Wallis). C: quantitative PCR experiments.
Bar graph representing amount of Nav1.5 mRNA in
control myocytes or treated with 1 M Aldo or with
1 M dexamethasone for 24 h. Number of mice is
indicated in bars. For each animal analysis was
performed in duplicate; results were obtained as
cycle Ct and normalized to the reference gene
GAPDH. D: representative Western blots showing
levels of expression of Nav1.5, Nedd4–2, phospho-
Nedd4–2, Nedd4–1, Sgk1, and 1-Nav subunit un-
der control, Aldo, and dexamethasone conditions.
Specificity of Nav1.5 antibody was tested using
transfected HEK-293 cells. Forty micrograms of
protein were loaded for the HEK-293 lysates, and
80 g of protein were loaded for myocytes lysates.
Three of such experiments yielded comparable re-
sults. Protein loading was controlled by anti-actin
immunoblotting. E: control anti-Nav1.5 Western
blot performed with increasing amounts of total
protein (40, 60, and 80 g/lane).
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biased by the lack of specificity of the MR and GR agonists and
inhibitors (12), it may be proposed that this issue should be
more adequately addressed using cellular or animal models
knocked out for the specific receptors (4).
In the present study, the INa was significantly increased by
10 and 100 nM of aldosterone. Such high concentrations may
be relevant in the context of HF-induced hyperaldosteronemia
because intracardiac aldosterone levels of 16 nM have been
reported in rat myocardium (36).
We also obtained evidence that cardiac INa is upregulated by
the glucocorticoid dexamethasone. Only few studies have ad-
dressed the question of regulation of cardiac ion channels by
glucocorticoids. Cardiomyocytes from neonatal mice treated
for 7 days with dexamethasone displayed increased ICa and
decreased Ito (42), a finding that is qualitatively similar to the
effect of aldosterone on adult rat myocytes (2). It therefore
appears that, in the heart, the activation of both gluco- and
mineralocorticoid pathways may lead to similar effects on ion
channels. However, as mentioned above, the dissection of the
two pathways, and their possible overlap, can only be ade-
quately performed using specific knock-out models. In hu-
mans, little is known about the role of steroid treatment on
cardiac channel function. It should, however, be mentioned
that corticosteroid therapy has been reported to be very effec-
tive in decreasing the arrhythmic manifestations caused by a
loss-of-function mutation of Nav1.5 in two pediatric patients
(38). The findings of the present study may, in part, underlie
this beneficial effect.
Cellular mechanisms of aldosterone-dependent regulation
of cardiac ion channels. Aldosterone exerts genomic and
nongenomic effects on its cellular targets (13). Similarly to the
effect on ICa in rat ventricular cells (3), we did not observe any
short-term (likely nongenomic) effect of aldosterone acute
perfusion on mouse myocytes INa. In contrast, INa was in-
creased after 24 h incubation with aldosterone. Again, as
reported for ICa (3), inhibition of gene transcription and protein
translation inhibited the aldosterone-dependent stimulation of
INa. In addition, we report here that brefeldin A, known to
block the secretory pathway of membrane proteins (21), abol-
ished the INa increase caused by aldosterone incubation. These
findings suggest that the genes regulated by aldosterone are
either encoding the channel itself or proteins involved in
channel trafficking or stabilization at the plasma membrane.
However, the quantitative RT-PCR and Western blot analysis
of the myocytes treated for 24 h with aldosterone and dexa-
methasone did not reveal any significant increase in mRNA
levels nor in the total cellular pool of Nav1.5 protein, which
may have explained the larger INa. A similar result was ob-
tained when analyzing the mRNA and total cellular expression
of Cav1.2 of aldosterone-treated cells. These surprising find-
ings strongly suggest that, in this model, the observed increase
in INa and ICa are due to a redistribution of the channels located
in an intracellular pool (48) toward the cell membrane com-
partment. In fact, such a “shuttling” mechanism is known to be
important for the action of many hormones [vasopressin (5)
and insulin (43), for instance] on the trafficking of membrane
transporters. However, because of a lack of sensitive and
reproducible techniques, we were not able to provide direct
evidence supporting this hypothesis.
Little is known about the molecular determinants of traffick-
ing and membrane turnover of Nav1.5. In a recent work (29),
interaction of Nav1.5 with ankyrin-G has been proposed to be
necessary for proper targeting of the channel to the plasma
membrane. On the other hand, because we have previously
shown that, in heterologous expression systems, Nav1.5 chan-
nel density at the plasma membrane may be regulated by E3
ubiquitin ligases of the Nedd4 family (35, 41), we also inves-
tigated the expression level of Nedd4–1 and Nedd4–2. How-
ever, under these experimental conditions, neither aldosterone
nor dexamethasone modified their expression in isolated car-
diac myocytes. In Xenopus oocytes, the protein kinase Sgk1,
known to be induced by aldosterone in the kidney (7), has been
shown to phosphorylate and inactivate Nedd4–2 (10). How-
ever, using an anti-phospho-Nedd4–2 antibody (15), we did
not see any aldosterone-induced increase in phosphorylation,
suggesting that decreased ubiquitination of Nav1.5 by
Nedd4–2 is not involved in the observed phenomenon. These
results are in line with the fact that Sgk1 protein was not found
to be upregulated (Fig. 6D) and are consistent with the obser-
vation that the Sgk1 gene is not increased upon aldosterone
treatment in heart (44). The Nav 1-subunit has been reported
to increase the Nav1.5-mediated currents in expression models
(18). However, this protein was not found to be upregulated by
aldosterone and is, therefore, not likely to be involved in the
observed phenomenon.
A systematic investigation, such as a comprehensive tran-
scriptome analysis of myocytes treated with aldosterone or
dexamethasone, would be needed to understand more thor-
oughly the molecular and cellular mechanisms underlying the
observed regulation of cardiac ion channels.
Pathophysiological relevance of aldosterone-dependent INa
increase. The arrhythmogenic mechanisms underlying SCD in
the context of HF are multiple and complex (39). Cardiac Na
current alterations have been implicated in a large number of
arrhythmic syndromes caused by mutations of SCN5A, the
gene encoding Nav1.5 (37). However, the role of Nav1.5 in
acquired cardiac disorders such as ischemic heart disease and
HF is not well understood. In animal studies, a downregulation
of the cardiac Na channel protein has been reported in dog
models of ischemic heart disease (47) and tachyarrhythmia-
induced HF (45). In contrast, in guinea pigs in which HF was
obtained by banding of the thoracic aorta (chronic pressure
overload-induced HF), an INa increase of up to about 100%
was reported (1). APD prolongation, as observed in this work
and in Be´nitah’s studies (2, 3, 30), is an important arrhythmo-
genic factor in the etiology of SCD in the context of HF (39).
It can be hypothesized that aldosterone-dependent upregulation
of both depolarizing INa and ICa, as well as downregulation of
K currents, may all participate in a synergistic manner to the
AP prolongation. Upregulation of late INa, which may contrib-
ute to AP prolongation, has been reported in different models
of HF (27, 40). Addressing the question whether such late INa
may also be regulated by steroid hormones represents one of
our future tasks. Altogether, these findings illustrate that dys-
regulation of the cardiac Na channel expression is very much
dependent on the experimental model investigated, and it may
be therefore possible that the aldosterone-induced increase in
INa described here is only present in some specific forms of HF
in humans. However, based on the clear beneficial effect of
spironolactone and eplerenone on SCD, these aspects deserve
to be investigated in future studies.
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 V. Discussions and perspectives 
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Regulation of the expression of Nav1.5, the cardiac voltage-gated sodium channel 
V.1 The regulation of Nav1.5 by the dystrophin 
multiprotein complex 
During my thesis I have addressed different aspects regarding the regulation of 
Nav1.5. At the beginning of this study, little was known about the interaction between 
Nav1.5 and the dystrophin multiprotein complex (DMC). Previous studies had 
reported that the sodium channel was interacting with syntrophin proteins however 
nothing was known about the functional consequences of this interaction in the 
heart73, 75. In our study, we observed that Nav1.5 was associated with dystrophin and 
we took advantage of the mdx5cv mouse model to investigate the role of this 
interaction.  
This chapter reports the different hypothesis that we formulated based on our 
experimental results, and it also describes our view of the sodium channel regulatory 
mechanisms. 
V.1.1 Dystrophin interacts with Nav1.5 
In order to identify cardiac proteins interacting with the sodium channel, we 
used mass spectrometry and pull downs experiments with GST-fusion proteins of the 
last 66 amino acids of Nav1.5. We showed that the PDZ-domain binding motif of 
Nav1.5 (formed by the last three residues SIV) was interacting with the PDZ-domain 
of α1, β1 or β2-syntrophin. We obtained evidence that interaction of the sodium 
channel with the DMC was occurring in mouse and guinea pig ventricular lysates, 
and also in human atrial appendage samples. In addition, we showed that a direct 
interaction between the PY-motif of Nav1.5 and the WW-domain of dystrophin was 
not likely to occur. Besides our results, other studies have also reported that ion 
channels bearing PDZ-domain binding motif such as Kir2.x in cardiac cells, Nav1.4 
and aquaporin-4 in skeletal cells could interact with the DMC. Therefore it appears 
that interaction of ion channels with syntrophin proteins and DMC is a common 
mechanism in skeletal and cardiac myocytes. 
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In order to confirm the interaction of the sodium channel with the DMC, we 
performed immunolocalization stainings. Unfortunately, despite the use of several 
antibodies, either on isolated cardiomyocytes or on heart sections, we never obtained 
a convincing Nav1.5 staining and, as a result, failed to show co-localization of sodium 
channels with dystrophin in cardiomyocytes. Fortunately, other groups have been 
able to show that Nav1.5 was localized both at intercalated discs as well as at lateral 
membranes of cardiomyocytes167-169. Immunohistochemistry experiments have 
revealed that dystrophin was localized at lateral membranes of cardiomyocytes but 
not at intercalated discs. These results, shown in human170, rats171 and mouse 
(personal data not shown), suggest that dystrophin and Nav1.5 can only interact at 
the level of lateral membranes of cardiomyocytes.  
Thus, we hypothesized that two pools of sodium channels could coexist in 
cardiomyocytes; a first pool which could be associated with DMC at lateral 
membranes, and a second pool could be localized at the intercalated discs. We are 
currently investigating whether proteins of the MAGUK family could interact with 
Nav1.5 at the intercalated discs. Recently, Baba and co-workers169 have reported that 
cardiomyocytes from infarcted dog heart displayed an important loss of sodium 
channel at lateral membranes with no modification of sodium channels at intercalated 
discs. These results support the existence of at least two distinct Nav1.5 pools, and 
suggest that sodium channels present in the lateral membranes of cardiomyocytes 
are playing a role in conduction of cardiac impulses.  
V.1.2 Nav1.5 protein content is decreased in mdx5cv mice 
Following pull-down experiments which revealed association of Nav1.5 and 
dystrophin, we performed Western blots on mdx5cv mice with the aim to investigate 
the consequences of dystrophin deficiency on the sodium channel. Our results 
indicated that the Nav1.5 protein level was decreased by ~50% in cardiomyocytes of 
mdx5cv mice as compared to controls, with no modification of mRNA levels. First, 
these results suggested that dystrophin could be involved in the regulation of Nav1.5 
stabilization/degradation or alteration of translation. Second, these results are 
consistent with the “two Nav1.5 pools” hypothesis since total dystrophin deficiency 
only leads to a decrease of half the total amount of sodium channels. The remaining 
channels (i.e. 50%) could represent the pool of proteins located at the level of 
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intercalated discs which does no interact with DMC. In order to test our hypothesis, 
Nav1.5 immunochemistry could be performed on control and mdx5cv cardiomyocytes. 
We could also perform cell attach patch-clamp recording on lateral membranes of 
control and mdx5cv cardiomyocytes to monitor the amount of Nav1.5 localized at this 
region. 
Due to membrane leak and calcium homeostasis alteration, it has been shown 
that the proteolytic activity (mainly calpain proteases) is increased in mdx mice127. 
Therefore, one could speculate that the decrease in Nav1.5 content of mdx5cv 
cardiomyocytes is the result of non-specific proteolysis or of the loss of interaction 
with DMC (which could be involved in stabilization of the sodium channel). We 
observed that Nav1.5 was specifically decreased in mdx5cv mice and that other 
membrane proteins such as Cav1.2 or Na-K,ATPase were not affected. This 
suggests that a non specific proteolytic mechanism is not likely to be involved in this 
process. In addition, a small reduction in the protein content of Kir2.1 was also 
observed and, interestingly, Kir channels possess a PDZ-domain binding motif and 
were shown to interact with the DMC172. Additional experiments could be performed 
in order to determine whether the decrease of Nav1.5 is due to a loss of interaction 
with DMC or to non-specific proteolysis. For instance we could take advantage of rat 
cardiomyocytes viral infection approaches to express small peptides either 
corresponding to the PDZ domain-binding motif of Nav1.5 or to PDZ domain of 
syntrophin. Using this approach we may be able to compete for the interaction of 
Nav1.5 with syntrophin. Electrophysiological or biochemical experiments could 
therefore indicate if the interaction with DMC is crucial for the stability of the sodium 
channel. 
V.1.3 INa is decreased in mdx5cv mice 
In order to test for the functional consequences of the reduction of ~50% of the total 
amount of protein, patch-clamp experiments were conducted on control and mdx5cv 
isolated cardiomyocytes. We observed that the sodium current was decreased by 
~30% in dystrophin-deficient cardiomyocytes as compared to control. Assuming that 
single channel conductance is similar in control and mdx5cv mice, we can postulate 
that the sodium current represents the amount of Nav1.5 channels at the plasma 
membrane. Therefore, we may speculate that the fact that mdx5cv mice have ~30% 
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less channel at the plasma membrane with a ~50% reduction of the total Nav1.5 
protein content may reflect the existence of an intracellular pool of sodium channel in 
control mice. Zimmer and coll.173 have reported that intracellular pools of sodium 
channel could be detected in dog cardiomyocytes. The existence of an intracellular 
pool of protein is supported by another study performed in our group where we 
observed that a treatment with aldosterone increased the sodium current of mice 
cardiomyocytes with no modification of the total Nav1.5 protein level5. However due 
to the difference in the experimental procedures, we cannot determine whether the 
difference between ~30% (i.e. INa) and ~50% (i.e. Nav1.5 protein) is significant. 
V.1.4 mdx5cv mice display cardiac conduction defects 
The voltage-gated sodium channel is crucial for cardiac excitation and 
conduction. Reduction of the sodium current has been associated with cardiac 
dysfunctions (e.g. Brugada syndrome and conduction diseases). Therefore, we 
measured ECGs of control and mdx5cv mice to detect potential consequences of a 
~30% reduction of the sodium current. Our results indicated that the QRS complex 
duration was increased by 18%. These results are consistent with a study performed 
by Royer and coll. where the authors measured a 39% increase in the QRS complex 
duration in a mice strain having a 50% reduction of INa (SCN5A heterozygous 
mice)174. In addition, computational data from Shaw and Rudy175 indicate that a 
reduction of the sodium current by 29% would lead to a prolongation of the duration 
of 18%, which matches with our results. Histological analyses revealed no sign of 
fibrosis or hypertrophy in 10-12 weeks old mdx5cv mice. Since connexin-43 levels are 
not modified, we propose that the cardiac electrical alterations of mdx5cv mice 
constitute a “pure” sodium channel phenotype. It is known that the density of the 
sodium current plays a crucial role in the conduction of the electrical impulse30. In 
particular based on mathematical simulations, Kucera and coll.32 have shown that the 
sodium current generated by Nav1.5 localized at intercalated discs of cardiomyocytes 
could modulate cardiac conduction. However, this conclusion was based on the 
different assumptions, including that most of the sodium channels are located at 
intercalated discs, an issue which is not yet elucidated. According to the two Nav1.5 
pools hypothesis (see section V.1.1), our results suggest that INa, generated by the 
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pool of Nav1.5 localized at the lateral membranes of cardiomyocytes, could also be 
crucial for cardiac conduction.   
V.1.5 MG132 rescues Nav1.5 and INa of mdx5cv mice 
Since it was proposed that ubiquitylation could be a regulatory mechanism of Nav1.5, 
in a set of pilot experiments, we used the proteasome inhibitor MG132 to study the 
implication of the ubiquitin-proteasome pathway in the decrease of Nav1.5 in mdx5cv 
mice. Upon MG132 treatment we observed that the total amount of Nav1.5 in mdx5cv 
mice was re-established to the level of control mice. In addition, the sodium current 
was also restored to a level similar to control mice. These observations suggest that 
MG132 may inhibit the degradation of Nav1.5 and that the proteasome is either 
directly or indirectly implicated in the degradation of the sodium current. Indeed, 
proteasome is implicated in the degradation of ubiquitylated proteins (see II.2.3.3) 
and Nav1.5 was shown to be ubiquitylated in cardiomyocytes3, therefore the 
proteasome may directly degrade the sodium channel. However, membrane 
associated proteins can be targeted to the endocytosis lysosome pathway which is 
itself regulated by ubiquitin sorting signals176. In addition the proteasome may be 
implicated in the regulation of ubiquitylated endocytosis proteins56. Therefore, it 
would be very important to perform additional experiments using endocytosis or 
lysosome inhibitors to determine whether Nav1.5 degradation is carried by the 
proteasome or by the lysosome. 
V.1.6 Nav1.5 ubiquitylation is decreased in mdx5cv mice upon 
MG132 treatment 
It is important to mention that these results are preliminary and that additional 
experiments should be performed in order to confirm our interpretations. 
We performed Nav1.5 immunoprecipitations in order to investigate the level of 
monoubiquitylation of the channel, using specific ubiquitin antibodies. However this 
approach failed to demonstrate convincingly the monoubiquitylation of the channel. 
Therefore, we used S5a fusion proteins to precipitate the entire polyubiquitylated 
protein fraction of the cardiomyocyte lysate, and used a specific anti-Nav1.5 antibody 
to reveal the amount of ubiquitylated channels. We observed that MG132 treatment 
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was associated with a strong reduction in the ubiquitylation level of Nav1.5 in mdx5cv 
cardiomyocytes. However, MG132 treatment can lead to a depletion of the free 
ubiquitin in the cell177. This phenomenon could induce both a decrease of 
ubiquitylation level of Nav1.5 and an important reduction of the endocytosis and 
lysosomal activity and thus lead to an increase of Nav1.5 at the plasma membrane. 
Therefore additional experiments should be performed in order to determine if the 
cells are ubiquitin depleted. 
V.2 The regulation of Nav1.5 by aldosterone 
During my thesis, I also investigated the regulation of the cardiac sodium 
channel by mineralocorticoid and glucocorticoid hormones. Previous studies by 
Benitah and coll.140, 141 have reported that aldosterone could increase ICa and 
decrease Ito in rat cardiomyocytes, leading to a prolongation of the action potential 
duration (APD). However the effect of aldosterone on the sodium current had never 
been studied so far. 
In this study, we reported that a 24 h treatment of mouse ventricular 
cardiomyocytes with 10 nM, 100 nM or 1 µM aldosterone significantly increased the 
sodium current. Similarly to Benitah and coll.140, we reported a prolongation of the 
action potential duration (APD) upon aldosterone treatment. The effect of aldosterone 
on the sodium current was blocked by the mineralocorticoid receptor (MR) antagonist 
spironolactone suggesting the implication of MR in the aldosterone response.  
However, with regards to the high drug concentrations and the lack of specificity of 
MR and GR agonists and inhibitors (e.g. spironolactone binds GR with an apparent 
Kd of 2µM178) used in our experiments, we may not have been able to determine 
which receptor was involved in the aldosterone-mediated INa increase.  In addition, 
11-β-hydroxy-steroid-dehydrogenase type II could protect MR against cortisol 
occupancy in the heart is still a matter of controversy. In our experiments, high doses 
of aldosterone were used to induce INa increase (ranging from 10 nM to 1 µM) and 
one can easily challenge the physiological relevance of the observed effects. 
Silvestre and coll.150 have measured aldosterone concentrations in rat myocardium 
as elevated as 16 nM, which may suggest that our observations are relevant in case 
of hyperaldosteronemia, however these results have been challenged by several 
groups (see section II.4.3).  
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With the aim to investigate the mechanisms underlying aldosterone-mediated 
INa increase, we used inhibitors of transcription (actinomycine D), inhibitors of protein 
translation (cycloheximide) and a blocker of the secretory pathway (Brefeldin A). Our 
results indicated that all these drugs blocked the aldosterone response, suggesting 
that aldosterone effect was mediated by gene expression. However, neither Nav1.5 
mRNA nor the protein level was modified upon aldosterone treatment, indicating that 
the drugs were not acting directly on Nav1.5 gene. Therefore we hypothesized that 
the observed INa increase could be due to the redistribution of intracellular pool of 
sodium channels173 toward the plasma membrane. Such mechanism of short-term 
hormone action has previously been described for vasopressin and insulin179, 180.  
The voltage gated sodium current is essential for cardiac function and 
numerous mutations of SCN5A are associated with cardiac pathologies. The role of 
the sodium channel in acquired cardiac diseases such as heart failure is not well 
defined. APD prolongation observed in our study5 and others140 is an important 
arrhythmogenic factor that may result from multiple ion current alterations (i.e. INa, ICa, 
Ito). However, based on the beneficial effects of MR antagonists (spironolactone and 
eplerenone) on the mortality of patients with heart failure142, 143, further investigations 
should be carried out on the mechanisms of corticosteroid action on cardiac ion 
currents. 
In conclusion, this study reports for the first time that mineralocorticoids and 
glucocorticoids increase the sodium current in mouse cardiomyocytes. However, 
further investigations are needed in order to determine to which receptor aldosterone 
is binding to. GR and MR knock-out mice are being bred in our department of 
pharmacology and toxicology. Although total GR or MR deficiency is lethal at birth, 
patch-clamp experiments could be made on newborn mice cardiomyocytes to 
determine the pathway of aldosterone action. In addition, immunocytochemical 
experiments should be carried out to investigate the localization of Nav1.5 and 
eventually reveal the presence of intracellular pools of sodium channel in mouse 
cardiomyocytes.  
 
Taking together the experimental evidences we obtained, we may postulate that 
dystrophin stabilizes Nav1.5 at the plasma membrane and may prevent its 
ubiquitylation and/or its endocytosis. In dystrophin-deficient mice, the ion channel is 
no longer protected and undergoes ubiquitylation and/or internalization before being 
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degraded. MG132 treatment experiments could indicate that the proteasome is not 
directly implicated in the degradation of Nav1.5. We hypothesized that treatment with 
the proteasome inhibitor could alter the endocytosis machinery which regulates the 
amount of sodium channel at the plasma membrane; however, further investigations 
are needed in order to elucidate the mechanisms of Nav1.5 degradation in control 
and mdx5cv mice.  For instance, we could perform immunocytochemistry experiments 
on cardiomyocytes and study colocalization of the sodium channel with endocytic 
vesicles or lysosomal markers. In order to bypass the lack of specificity of the 
commercially available anti-Nav1.5 antibodies, we could use viral vectors to 
transduce tagged WT and PDZ-binding domain deleted constructs of Nav1.5. This 
type of technique has been successfully used on rat adult cardiomyocytes181.  Thus 
we might be able to determine the difference in protein trafficking or stability in 
absence of binding to the DMC.  
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The voltage-gated sodium channel Nav1.5 is essential for the generation of the 
action potential and for electrical cardiac conduction. The importance of this channel 
has been attested by the study of numerous naturally occurring mutations of SCN5A 
associated with cardiac pathologies such as the congenital long QT syndrome, 
Brugada syndrome and progressive conduction disorders.  
During the past decade, an important number of studies have investigated the 
alterations of the sodium channel that can lead to arrhythmias. Only recently, 
scientists started to investigate the regulatory mechanisms of ion channels as 
potential causes of cardiac arrhythmias. The sodium current of cardiomyocytes 
depends on the amount of Nav1.5 protein at the plasma membrane of 
cardiomyocytes. The experiments performed during my thesis have investigated the 
targeting, the stabilization, and the degradation of the sodium channel at the plasma 
membrane (Figure 21). Our results suggest that the sodium current can be increased 
by distribution of intracellular pools of proteins to the plasma membrane (e.g. upon 
aldosterone stimulation). We also showed that interaction with other membrane 
proteins (e.g. interaction with DMC) is required for the stabilization of Nav1.5 at the 
plasma membrane. Finally, we provided experimental evidence suggesting that the 
sodium channel can be ubiquitylated by so far unknown ubiquitin. These results are 
important because they reveal the complexity of Nav1.5 regulation. This complexity 
will have to be taken into account when developing new therapeutic strategies 
targeting this channel for the treatment of arrhythmic diseases. 
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Figure 21: Diagram illustrating a hypothetical model of Nav1.5 regulation. 
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